

CEMCHD 2022 • 18TH European Meeting
on Complement in Human Disease
Bern Switzerland • 26.-29.08.2022



PROGRAM

2022

18th

EUROPEAN MEETING ON

COMPLEMENT IN

HUMAN DISEASE

Search function:

Press Ctrl+F

WELCOME NOTE

Dear colleagues,

We warmly welcome you to Bern, the beautiful Capital of Switzerland, for the 18th European Meeting on Complement in Human Disease (EMCHD), from August 26-29, 2022!

Due to the COVID-19 pandemic, this will be the first international complement meeting to happen on-site for almost 3 years. And this meeting takes place while a bloody war is going on in Europe, killing thousands of people and ruining the lives of millions. These sad circumstances once again highlight the importance of the advancement of science to 'ease the burden of human existence', as Bert Brecht once pointed out, and of international solidarity, mutual support and understanding across borders and nations.

It is in this spirit that we – on behalf of the European Complement Network – look forward to meeting colleagues from all over the world and to foster scientific advancement in the field of complement to fight human disease.

See you in Bern at the EMCHD 2022!

Robert Rieben

Daniel Ricklin

Marten Trendelenburg

Verena Schröder

Sacha Zeerleder

Uyen Vo

and the team of The Meeting Planners

CONTENT

WELCOME NOTE	2
COMMITTEE & BOARDS	4
LOCAL ORGANIZING COMMITTEE	4
ECN BOARD.....	5
ECN BOARD MEMBERS.....	5
GENERAL INFORMATION	6
ABSTRACT BOOK.....	6
POSTER SESSION	6
WI-FI LOGIN	6
VENUE	6
LUNCH & REFRESHMENTS	6
PRESENTATIONS	6
BADGES.....	6
ATTENDANCE CERTIFICATES	6
REGISTRATION DESK OPENING HOURS.....	6
CONGRESS AGENCY & BERN WELCOME	6
FLOOR PLAN & EXHIBITION AREA.....	7
OTHER INFORMATION	7
CITY INFORMATION.....	7
.....	8
EMERGENCY CONTACTS	8
COVID TEST CENTER	8
SOCIAL PROGRAM.....	9
AUGUST 26, 2022, 15:00-17:00	9
AUGUST 26, 2022, 18:00-20:00	9
AUGUST 27, 2022, 19:00-22:00	9
AUGUST 28, 2022, FROM 16:45 (DINNER STARTS AT 19:00).....	10
SCIENTIFIC PROGRAM	12
FRIDAY, AUGUST 26, 2022 – TEACHING DAY & EXCURSION	12
SATURDAY, AUGUST 27, 2022 – EMCHD MEETING	14
SUNDAY, AUGUST 28, 2022 – EMCHD MEETING	17
MONDAY, AUGUST 29, 2022 – EMCHD MEETING	20
POSTER EXPO	23
POSTERS	23
POSTER AUTHORS INDEX.....	34
LATE BREAKING POSTERS	36
LATE BREAKING POSTER AUTHORS INDEX.....	38
SPONSORS	39

COMMITTEE & BOARDS

LOCAL ORGANIZING COMMITTEE



Prof. Dr. Robert Rieben

Department for BioMedical Research
University of Bern



Prof. Dr. Daniel Ricklin

Department of Pharmaceutical Sciences
University of Basel



Prof. Dr. Marten Trendelenburg

Division of Internal Medicine and Laboratory
for Clinical Immunology
University Hospital Basel



Prof. Dr. Verena Schroeder

Department for BioMedical Research
University of Bern



Prof. Dr. Sacha Zeerleder

Department of Hematology, Division of
Internal medicine, Kantonsspital Lucerne
and University of Berne



Uyen Vo

Conference Secretary
Department for BioMedical Research
University of Bern

ECN BOARD

President:

Reinhard Würzner

Austria

Division of Hygiene &
Medical Microbiology
Department of Hygiene,
Microbiology and Public
Health, Medical
University of Innsbruck
Schöpfstr. 41
A-6020 Innsbruck
Austria

Secretary:

Christoph Schmidt

Germany

Institute of
Pharmacology of
Natural Products &
Clinical Pharmacology
Ulm University
Helmholtzstr. 20
D-89081 Ulm
Germany

Treasurer:

Simon Clark

United Kingdom

Institute for Ophthalmic
Research, Eberhard
Karls University of
Tübingen
Elfriede-Auhorn-Straße
7, D-72076 Tübingen
Germany

ECN BOARD MEMBERS

Bo Nilsson, Sweden

Department of Chemistry and Biomedicine,
Linnaeus University, Kalmar, Sweden.

Nicole Thielens, France

University of Grenoble Alpes, Institut de
Biologie Structurale, Grenoble

Marten Trendelenburg, Switzerland

Department of Biomedicine, University
Hospital, Basel

Elena Volokhina, The Netherlands

Department of Pediatric Nephrology,
Radboud University Medical Center,
Nijmegen

Elena Goicoechea de Jorge, Spain

Department of Microbiology, Complutense
University School of Medicine, Madrid

Mihály Józsi, Hungary

Department of Immunology, ELTE Eötvös
Loránd University, Budapest

Per Nilsson, Norway

Department of Immunology, Oslo
University Hospital, University of Oslo,
Oslo

Mikkel-Ole Skjødt, Denmark

Institute of Immunology and Microbiology,
University of Copenhagen, Copenhagen



GENERAL INFORMATION

ABSTRACT BOOK

The abstract book can be downloaded from the website from August 22. A notification will be send to all delegates once the file is available.

POSTER SESSION

Saturday, August 27, 2022 - Odd abstract numbers.

Sunday, August 28, 2022 - Even abstract numbers.

Poster mounting: August 27 from 7.30

Dismantle: August 29 from 14.00

WI-FI LOGIN

- If you have eduroam installed on your computer or mobile devices, WLAN connection will be automatic.
- Choose the network: public-unibe. You will be automatically redirect to mpp.unibe.ch.
- Choose: Request a temporary access code by SMS - Enter mobile number and code: nngc-uwsj (Foreign guests must include the country code)

VENUE

Campus vonRoll, University of Bern, Fabrikstrasse 6-8, 3012 Bern

All scientific sessions take place at Auditorium 001, Building Fab6

Poster: Hintere Gasse, Building Fab8

Exhibition, lunch, coffee: Vordere Gasse Building Fab8

LUNCH & REFRESHMENTS

Lunch and coffee breaks are included in the registration fee and will be served in the exhibition area. The serving times can be found in the detailed program.

PRESENTATIONS

Presenter should save the presentation file(s) on USB stick or external HD and bring the stick/HD to the meeting room where he/she will present (please refer to the final program). The format of your presentation should be 16/9 and Powerpoint. There will be student helpers in each of the meeting rooms to receive and upload the files. Presenters are requested to deliver the files latest at the break before the presenting session - for example: if there is only a lunch break before your session at 16:00, then the file needs to be delivered latest during this lunch break.

BADGES

Name badge should be picked up at the registration desk and is required for accessing lectures, lunch and coffee servings, exhibition area and social events. Please wear your name badge throughout the conference.

ATTENDANCE CERTIFICATES

Participants will receive their Certificates of Attendance by email after the congress.

REGISTRATION DESK OPENING HOURS

Friday, August 26:	Saturday, August 27:	Sunday, August 28:	Monday, August 29:
07:00-14:30	07:00-17:30	07:00-16:00	07:00-15:00


CONGRESS AGENCY & BERN WELCOME

The Meeting Planners: Phone: (+45) 60217421 - E-mail: req@meetingplanners.dk

For questions about hotel accommodation: Bern Welcome - Phone: (+41) 313281260

E-mail: meetings@bern.com

FLOOR PLAN & EXHIBITION AREA




OTHER INFORMATION

CITY INFORMATION

The city of Bern, a UNESCO world heritage, is the capital of Switzerland and, including the surrounding urban area, has approximately 400.000 inhabitants.

The city offers state-of-the-art facilities for congresses, seminars and evening functions. Thanks to the historic charm of Bern and because of its proximity to the Swiss Alps, an attractive social program with exciting leisure activities can complement any main event.

Visit one of the panoramic peaks in the nearby Bernese Oberland, see how the famous Emmental cheese is produced at a show dairy or take a stroll through the covered arcades of the medieval old town. There is something for everyone here.



1. Congress Venue: Fabrikstrasse 6 & 8, 3012 Bern

2. Bern Train station

3. Kornhauskeller: Kornhauspl. 18, 3011 Bern

4. Distelzwangkeller: Gerechtigkeitsgasse 79, 3011 Bern

EMERGENCY CONTACTS

Ambulance: 144

Police: 117 & 112

Bern Police: +4131 638 81 11

Fire Brigade: 118

COVID TEST CENTER

In Bern: <https://www.viselio.com/en/home>

At Zürich Airport: you can find via this homepage: <https://www.flughafen-zuerich.ch/en/passengers/news/corona/general-information> or <https://www.viselio.com/en/home>



Driven by Our Promise

cslbehring.com
csl.com

SOCIAL PROGRAM

AUGUST 26, 2022, 15:00-17:00

City Tour.

Duration: 2 hours

Meeting Point: In front of the Clock Tower

Pax: Max. 20 persons per group

Language: English

Costs: CHF 45.00/person/2 hours.

The price includes 7,7% VAT.

Booking: via conference registration form




AUGUST 26, 2022, 18:00-20:00

Welcome reception at Kornhauskeller.

Price: free of charge for conference delegates

Address: Kornhauspl. 18, 3011 Bern



AUGUST 27, 2022, 19:00-22:00

Chair & Board Dinner at Distelzwangkeller

Access per invitation, by LOC

Address: Gerechtigkeitsgasse 79, 3011 Bern

Dress code: Casual



AUGUST 28, 2022, FROM 16:45 (DINNER STARTS AT 19:00)

Our conference dinner will take place in Lake of Lucerne, one of the most beautiful lakes in Switzerland.


Meeting point: Outside of University of Bern Campus vonRoll at 16:45.

Time: Meet for bus transfer at 16:45 and arrive in Lucerne at approximately 19:00. We will have the dinner onboard while cruising Lake of Lucerne (19:00-22:00). We will return by bus transfer and the estimated arrival time in Bern is 24:00.

Price: CHF 35 per delegate; CHF 125 for the accompanying guest (paid during registration)

Dress code: Casual





Rare Inspiration. Changing Lives.

At Alexion, our mission is to transform the lives of people affected by rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. alexion.com

SCIENTIFIC PROGRAM

FRIDAY, AUGUST 26, 2022 – TEACHING DAY & EXCURSION

Part 1: Overview lectures – Auditorium 001, Building Fab6

These lectures are open to everyone, no special registration needed

08.30 – 09.00	Coffee & croissants
09.00 – 09.05	WELCOME AND INTRODUCTION <i>Daniel Ricklin, Verena Schroeder</i>
09.05 – 09.25	OVERVIEW OF THE COMPLEMENT SYSTEM AND ITS CANONICAL ROLES IN HOST DEFENSE AND HOMEOSTASIS <i>Tom Mollnes</i>
09.25 – 09.45	NON-CANONICAL COMPLEMENT FUNCTIONS AND CROSSTALK WITH OTHER DEFENSE SYSTEMS <i>Leendert Trouw</i>
09.45 – 10.05	COMPLotype & COMPLEMENTOPATHIES: COMPLEMENT AS LONG-TERM DISEASE CONTRIBUTOR <i>Claire Harris</i>
10.05 – 10.25	COMPLEMENT IN ACUTE-PHASE DISORDERS WITH A FOCUS ON BACTERIAL INFECTIONS AND SEPSIS <i>Suzan Rooijakkers</i>
10.25 – 10.45	COMPLEMENT AS TARGET FOR THERAPEUTIC INTERVENTION <i>Daniel Ricklin</i>
10.45 – 11.00	PRESENTATION OF ECCO (EARLY-CAREER COMPLEMENTOLOGISTS) <i>Nicole Schäfer (Video)</i>
11.00 – 11.30	Coffee break and exhibition

COLD AGGLUTININ DISEASE IS ABOUT MORE THAN AVOIDING THE COLD,

C1-ACTIVATED HEMOLYSIS CAN HAVE SEVERE CONSEQUENCES

CAD is a rare, chronic, autoimmune hemolytic anemia that could put patients at risk.^{1,2}

67% of patients with CAD who received unapproved therapy had a severe anemia event within the first 6 months.^{3*}

62% higher incidence of thromboembolic events found in US patients with CAD.^{4†}

Additional studies are needed to further understand the risks associated with CAD.

Learn more about Cold Agglutinin Disease (CAD) at www.understandCAD.com

References: 1. Berentsen S, Basika K, Tienniford GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. *Hematology*. 2007;12(5):361-370. 2. Mullins M, Jiang X, Bylina LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. *Blood Adv*. 2017;1(13):839-848. 3. Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. *Res Pract Thromb Haemost*. 2020;4(4):628-635.

*Data collected from 18 patients with at least 6 months of follow-up after initial therapy in a retrospective review of a healthcare database.
†In a sensitivity analysis of a retrospective claims-database study of US patients with CAD (n=425) vs a matched non-CAD population (n=4126), 26.8% (n=114/425) of patients with CAD experienced a TE vs 16.5% (n=680/4126) in the comparison cohort. aHR (95% CI): 1.80 (1.46-2.22). Because the primary analysis included patients with both CAD and CAS, this sensitivity analysis was performed to evaluate the estimated risk of TEs among patients presumed to have CAD specifically. 183 and 1747 patients from the initial CAD and matched cohorts, respectively, were excluded due to the presence of diagnostic codes known to be associated with CAS.

aHR=adjusted hazard ratio; CAD=Cold Agglutinin Disease; CAS=cold agglutinin syndrome; TE=thromboembolic event.

References: 1. Berentsen S, Basika K, Tienniford GE. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. *Hematology*. 2007;12(5):361-370. 2. Mullins M, Jiang X, Bylina LC, et al. Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization. *Blood Adv*. 2017;1(13):839-848. 3. Broome CM, Cunningham JM, Mullins M, et al. Increased risk of thrombotic events in cold agglutinin disease: a 10-year retrospective analysis. *Res Pract Thromb Haemost*. 2020;4(4):628-635.

All the references can be obtained from Sanofi upon request.

© 2021 Genzyme Corporation. All rights reserved. MAT-CH-2201075-v1.0-07/2022

sanofi

Part 2: Workshops

The workshops are intended for PhD students and junior researchers in the field.

Registration is required and participants indicate **two topics** of their choice.

Workshops take place at 11:30-12:30, and 12:45-13:45, and each topic is offered twice.

Methodology Topics: Complement methods in research & clinic		Room
1	COMPLEMENT DIAGNOSTICS <i>Zoltan Prohászka</i>	B005
2	COMPLEMENT GENETICS (COMPLEMENT GENES, GENOTYPING OF COMMON SNPs, ANALYSIS OF "BIG DATA" FROM SEQUENCING) <i>Santiago Rodriguez de Córdoba</i>	B007
3	COMPLEMENT METHODS FOR THE RESEARCH LAB <i>Christoph Schmidt</i>	B101
4	ANIMAL MODELS IN COMPLEMENT RESEARCH <i>Jörg Köhl</i>	B008
5	METHODS INVOLVING COMPLEMENT AND IMMUNE CELLS <i>Christian Karsten</i>	B102
Bench-to-bedside topics with a more clinical focus		
6	COMPLEMENT IN RENAL DISORDERS <i>Marina Noris</i> only at 12:45-13:45	B201
7	COMPLEMENT IN HEMOLYTIC DISORDERS <i>Sacha Zeerleder</i> only at 11:30-12:30	B202
8	COMPLEMENT IN CANCER <i>Lubka Roumenina</i>	B301
9	COMPLEMENT IN HUMAN DISEASE – THE CLINICIAN'S PERSPECTIVE <i>Marten Trendelenburg</i>	B302
10	COMPLEMENT IN TRANSPLANTATION, ISCHEMIC & THROMBOINFLAMMATORY CONDITIONS <i>Kristina Nilsson Ekdahl, Bo Nilsson</i>	B306
13.45 – 14.45	Lunch	
14.30 – 15.30	ICS Board Meeting Meeting room B005	
18.00 – 20.00	WELCOME RECEPTION AT KORNHAUSKELLER Welcome address: Prof. Christian Leumann, Rector University of Bern	

SATURDAY, AUGUST 27, 2022 – EMCHD MEETING

07.30 – 08.00	Coffee & croissants
08.00 – 08.15	WELCOME ADDRESS <i>Robert Rieben and Reinhard Würzner</i>
08.15 – 09.45	SCIENTIFIC SESSION I: STRUCTURE & FUNCTION Chairs: Nicole Thielens, Richard Pouw
08.15 – 08.30	10 HIGH-RESOLUTION IMAGING OF COMPLEMENT MOLECULES ON GRAM-NEGATIVE BACTERIA <i>Dani Heesterbeek, Johannes Schneider, Kok van Kessel Dennis, Doorduijn, Bart Bardoel, Jos van Strijp, Marek Basler, Suzan Rooijakkers</i>
08.30 – 08.45	75 STRUCTURAL INSIGHTS INTO THE HEXAMERIC FORM OF THE IGM FC-CORE DOMAIN AND ITS BINDING CHARACTERIZATION TO C1Q <i>Andrea J. Pinto, Leandro Estrozi, Isabelle Bally, Anne Chouquet, Véronique Rossi, Guy Schoehn, Nicole Thielens, Christine Gaboriaud, Wai Li Ling, Jean-Baptiste Reiser</i>
08.45 – 09.00	54 FUNCTIONAL CONSEQUENCES OF MISSENSE MUTATIONS AT POSITION 263 IN COMPLEMENT C2 PROTEIN <i>Alicja Kuźniewska, Marcel Thiel, Daria Kowalska, Stanisław Ołdziej, Emilia Ajrona, Santiago Rodriguez de Córdoba, Marcin Okrój, Aleksandra Urban</i>
09.00 – 09.15	119 RECOGNITION OF POST-TRANSLATIONAL LYSINE MODIFICATIONS BY THE LECTIN PATHWAY INITIATOR FICOLIN 3 <i>Linnea Lindelöf, David Eikrem, Kristina Nilsson Ekdahl, Peter Garred, Bo Nilsson, Oskar Eriksson</i>
09.15 – 09.30	183 MODULATION OF THE CLASSICAL COMPLEMENT PATHWAY BY FACTOR H-RELATED PROTEINS <i>Hani Hashim Hammad, Alexandra Papp, Ádám I. Csincsi, Barbara Uzonyi, Anna Blom, Józsi Mihály</i>
09.30 – 09.45	116 CRYSTAL STRUCTURE OF THE FACTOR H DOMAINS 8-14 UNCOVERS THE SIGNIFICANCE OF THE CENTRAL DOMAINS FOR THE DISCRIMINATION BETWEEN SELF AND NONSELF BY FACTOR H <i>Christoph Schmidt, Arthur Doppler, Dierk Niessing, Thomas Monecke</i>
09.45 – 10.15	Coffee break, Posters and Exhibition
10.15 – 11.00	KEYNOTE SPEECH I Introduction by Sacha Zeerleider DEVELOPMENT OF CYCLIC PEPTIDE INHIBITORS OF FXII AND OTHER PLASMA PROTEASES BY PHAGE DISPLAY <i>Prof. Christian Heinis, Swiss Federal Institute of Technology, Lausanne</i>
11.00 – 12.30	POSTER VIEWING SESSION I All topics: odd poster numbers. <i>Posters will be displayed during the whole congress</i>
12.30 – 14.00	Standing lunch, Exhibition

13.00 – 13.40	CSL BEHRING SYMPOSIUM Introduction by Rolf Spirig TARGETING COMPLEMENT AND OTHER PATHWAYS IN KIDNEY ISCHEMIA-REPERFUSION INJURY <i>Prof. Peter Cowan, St. Vincent's Hospital, Melbourne</i>
13.00 – 14.00	ECN Board Meeting Meeting room B005, Building Fab8
14.00 – 16.30	SCIENTIFIC SESSION II: CROSSTALK & NONCANONICAL FUNCTIONS Chairs: Lubka Roumenina, Verena Schroeder
14.00 – 14.15	49 ISOFORM-SPECIFIC BINDING OF APOLIPOPROTEIN E TO COMPLEMENT FACTOR H ALTERS AMYLOID-B-MEDIATED NEUROTOXICITY IN VITRO AND IN VIVO <i>Larisa Chernyaeva, Giorgio Ratti, Laura Teirilä, Uni Rankka, Satoshi Fudo, Anssi Pelkonen, Paula Korhonen, Katarzyna Leskinen, Salla Keskitalo, Kari Salokas, Christina Christodouloupolou, Katrina Crompton, Markku Varjosalo, Tarja Malm, Ville Leinonen, Angelika Chroni, Päivi Saavalainen, Seppo Meri, Adam Wollman, Eija Nissilä, Karita Haapasalo</i>
14.15 – 14.30	76 COMPLEMENT AND HAEMOSTASIS: EFFECTS OF COMPLEMENT INHIBITORS IN A MICROFLUIDIC BLEEDING MODEL <i>Murielle Golomangi, Jessie Kohler, Christin Lamers, Richard Pouw, Daniel Ricklin, Elaissa Trybus Hardy, Wilbur Lam, Verena Schroeder</i>
14.30 – 14.45	112 IN HUMAN MICROVASCULAR ENDOTHELIAL CELLS (HMEC-1) C5A/C5AR1 INDUCES VON WILLEBRAND FACTOR (VWF) RELEASE FROM WEIBEL-PALADE BODIES (WPBS) VIA ADENYLYL-CYCLASE ACTIVATION <i>Sistiana Aiello, Sara Gastoldi, Miriam Galbusera, Ariela Benigni, Giuseppe Remuzzi, Marina Noris</i>
14.45 – 15.00	43 CELL-INTRINSIC C3 MEDIATES PANCREATIC BETA-CELL SURVIVAL IN INFLAMMATORY AND CELL STRESS CONDITIONS <i>Ben King, Klaudia Kulak, Marina Mackay, Lucie Colineau, Anna Blom</i>
15.00 – 15.15	82 ALTERNATIVE SPLICING ENCODES INTRACELLULAR CD59 ISOFORMS WHICH MEDIATE INSULIN SECRETION, ARE DOWNREGULATED IN DIABETES, AND INTERACT WITH DNA, SUGGESTING INVOLVEMENT IN GENE TRANSCRIPTION REGULATION <i>Ewelina Golec, Alexander Ekstrom, Maciej Noga, Muhammad Omar Hmeadi, Per-Eric Lund, Bruno Villoutreix, Ulrika Krus, Katarzyna Wozniak, Olle Korsgren, Erik Renström, Sebastian Barg, Ben King, Anna Blom</i>
15.15 – 15.30	101 ANAPHYLATOXIN RECEPTORS REGULATE THE DIFFERENTIATION AND FUNCTION OF DENDRITIC CELLS SUBSETS FROM BONE MARROW-DERIVED PRECURSORS <i>Alicja Anna Nowacka, Sven Geisler, Chandrashekhar Pasare, Jörg Köhl</i>
15.30 – 16.00	Coffee break

16.00 – 16.45	CURRENT TOPICS I: COVID-19 <i>Speaker: Michael Osthoff</i> <i>Moderator: Marten Trendelenburg</i>
16.45 – 17.30	SCIENTIFIC SESSION III: AUTOIMMUNE DISEASE Chairs: Marten Trendelenburg, Anna Blom
16.45 – 17.00	29 POST-TRANSLATIONALLY MODIFIED PROTEINS BIND AND ACTIVATE COMPLEMENT LEADING TO INCREASED CELLULAR BINDING AND UPTAKE <i>Michelle van den Beukel, Stef van der Meulen, Lu Zhang, Nicole Borggreven, George Janssen, Peter van Veelen, Leendert Trouw</i>
17.00 – 17.15	86 C5AR2 DEFICIENCY AMELIORATES INFLAMMATION IN MURINE EPIDERMOLYSIS BULLOSA ACQUISITA BY REGULATING C5A- AND FC Γ R-MEDIATED FUNCTIONS OF NEUTROPHILS <i>Daniel Seiler, Marie Kleingarn, Katja Kähler, Tilo Freiwald, Jack Bibby, Caroline Gruner, Jovan Schanzenbacher, Elvira Ehlers-Jeske, Samyr Kenno, Christian Sadik, Enno Schmidt, Katja Bieber, Behdad Afzali, Jörg Köhl, Ralf Ludwig, Claudia Kemper, Christian Karsten</i>
17.15 – 17.30	124 A COMPLEMENT C3-NANobody INHIBITS THE AP CONVERTASE STABILIZATION MEDIATED BY ANTI-C3BBB AUTOANTIBODIES IN C3 GLOMERULOPATHY <i>Julia Roquigny, Veronique Frémeaux-Bacchi, Gregers Andersen, Lubka Roumenina, Seppo Meri, Marion Mandavit, Sophie Chauvet, Marie-Agnès Dragon-Durey</i>
19.00 – 22.00	LOC, Chair & Board Dinner, Distelzwangkeller, Gerechtigkeitsgasse 79, 3011 Bern

SUNDAY, AUGUST 28, 2022 – EMCHD MEETING

07.30 – 08.00	Coffee & croissants
08.00 – 09.30	SCIENTIFIC SESSION IV: THERAPEUTICS Chairs: Christoph Schmidt, Christina Lamers
08.00 – 08.15	45 IN VIVO INHIBITION OF ALTERNATIVE PATHWAY ACTIVITY VIA MASP-3 INHIBITOR OMS906 <i>Jason Cummings, Yi Li, Kathy Shaffer, Jeremy Freeman, Munehisa Yabuki, Thomas Dudler</i>
08.15 – 08.30	169 A POTENT, TARGETED, ENZYME-LIKE INHIBITOR OF ALL THREE COMPLEMENT ACTIVATION PATHWAYS <i>Arthur Dopler, Sophia Lang, Amira Akilah, Markus Huber-Lang, Christoph Schmidt</i>
08.30 – 08.45	130 THERAPEUTIC TARGETING OF FACTOR H TO INJURED TISSUES THROUGH LINKAGE WITH ANTI-C3D MAB DELIVERS POTENT AND DURABLE COMPLEMENT INHIBITION IN SKIN WITHOUT INHIBITING SYSTEMIC COMPLEMENT <i>Fei Liu, Sarah Ryan, Kelly Fahnoe, Jennifer Morgan, Purvi Mande, Shuyun Xu, Christine Lian, Katja Bieber, Enno Schmidt, Admar Verschoor, Ralf Ludwig, Joshua Thurman, Michael Holers, Shelia Violette, Stefan Wawersik</i>
08.45 – 09.00	173 CHARACTERIZATION OF A NOVEL SMALL INTERFERING RNA FOR COMPLEMENT REGULATION THROUGH TARGETED SILENCING OF C3 <i>Erik Richardson, Tara Barbour, Andrew Carvalho, Antoinette Hayes, Joshua Garlich, Kathrin Hultsch, Soham Mandal, Stephan Seiffert, Jochen Deckert, Anke Geick, Hans-Peter Vornlocher, David Eyerman, Lukas Scheibler</i>
09.00 – 09.15	147 DESIGN AND EVALUATION OF C3 INHIBITORS OF THE COMPSTATIN FAMILY WITH PROLONGED TARGET RESIDENCE TIME <i>Christina Lamers, Hughes Sarah, Ranillo Resuello, John Lambris, Daniel Ricklin</i>
09.15 – 09.30	126 PHARMACOKINETICS/PHARMACODYNAMICS OF KP104, A BI-FUNCTIONAL ANTIBODY FUSION PROTEIN INHIBITOR OF COMPLEMENT, IN C5/FCRN-HUMANIZED TRANSGENIC MICE AND Cynomolgus MONKEYS <i>Jay Ma, Xiang Gao, Takashi Miwa, Damodar Gullipalli, Sayaka Sato, Wenchoao Song, Xihua Zhu, Jianjun Zhang, Chaomei He, Helen HFu, Richard Lee, Frederick Beddingfield, Wenru Song, Ping Tsui</i>
09.30 – 10.00	Coffee break, Posters and Exhibition
10.00 – 10.45	KEYNOTE SPEECH II Introduction by Robert Rieben DECODING THE ROLES OF ENDOTHELIAL CELL HETEROGENEITY AND COMPLEMENT SYSTEM IN DISEASES AND REGENERATIVE MEDICINE BY SINGLE CELL AND SPATIALLY RESOLVED TRANSCRIPTOME ANALYSIS <i>Speaker: Prof. Yonglun Luo, Aarhus University, Denmark</i>

10.45 – 11.45	SCIENTIFIC SESSION V: ACTIVATION & REGULATION
	Chairs: Sacha Zeerleider, Mihaly Jozsi
10.45 – 11.00	181 GRANZYME K ELICITS A NEW PATHWAY FOR COMPLEMENT ACTIVATION <i>Carlos Donado, Helena Jonsson, Michael Brenner</i>
11.00 – 11.15	70 THE CONTRIBUTION OF THE ALTERNATIVE PATHWAY TO COMPLEMENT ACTIVATION DEPENDS ON THE STRENGTH OF CLASSICAL PATHWAY INITIATION <i>Esther de Boer, Astrid Thielin, Jeroen Langereis, Angela Kamp, Mieke Brouwer, Nienke Oskam, Marlieke Jongsma, Robbert Spaapen, Sacha Zeerleider, Richard Pouw, Gestur Vidarsson, Theo Rispens, Diana Wouters, Ilse Jongerius</i>
11.15 – 11.30	151 MOLECULAR CONDITIONS FOR THE ASSEMBLY OF INITIAL C3 AP CONVERTASES FORMED BY NATIVE C3 AT BIOMATERIAL SURFACES <i>Anna Adler, Vivek Anand Manivel, Kristina Nilsson Ekdahl Nilsson Bo, Karin Fromell</i>
11.30 – 11.45	162 QUANTIFICATION OF THE ZYMOGENICITY AND THE SUBSTRATE-INDUCED ACTIVITY ENHANCEMENT OF COMPLEMENT FACTOR D <i>Ráhel Dani, Gábor Oroszlán, Róbert Martinusz, Bernadett Dobos, Evelin Vadas, Péter Závodszy, Péter Gál, József Dobó</i>
11.45 – 13.30	POSTER VIEWING SESSION II All topics: even poster numbers <i>Posters will be displayed during the whole congress</i>
12.00 – 13.30	Standing Lunch, Posters and Exhibition
13.30 – 15.00	SCIENTIFIC SESSION VI: INFECTIOUS DISEASES
	Chairs: Reinhard Würzner, Suzan Rooijakkers
13.30 – 13.45	111 RECOGNITION AND INHIBITION OF SARS-COV-2 BY HUMORAL INNATE IMMUNITY PATTERN RECOGNITION MOLECULES <i>Cecilia Garlanda, Matteo Stravalaci, Isabel Pagani, Elvezia Maria Paraboschi, Sarah Mapelli, Andrea Cavalli, Barbara Bottazzi, Francesco Scavello, Nicasio Mancini, Milos Matkovic, Peter Garred, Rosanna Asselta, Elisa Vicenzi, Alberto Mantovani</i>
13.45 – 14.00	144 AUTOANTIBODIES AND COMPLEMENT ACTIVATION IN BRONCHOALVEOLAR LAVAGE AND TISSUES OF COVID-19 PATIENTS <i>Paolo Macor, Luca De Maso, Stefano Di Bella, Paolo Durigutto, Marcello Manfredi, Erik Roman-Pognuz, Verena Zerbato, Stella Bernardi, Rossana Bussani, Roberto Luzzati, PierLuigi Meroni, Francesco Tedesco</i>
14.00 – 14.15	109 HIV-1 TRANS INFECTION VIA TNTS IS IMPEDED BY TARGETING C5AR <i>Giulia Bertacchi, Doris Wilflingseder</i>

14.15 – 14.30	92 PROMOTING FC-FC INTERACTIONS BETWEEN ANTI-CAPSULAR ANTIBODIES PROVIDES STRONG IMMUNE PROTECTION AGAINST STREPTOCOCCUS PNEUMONIAE <i>Leire Aguinagalde Salazar, Maurits den Boer, Suzanne Castenmiller, Seline Zwarthoff, Carla Gosselaar-de Haas, Piet Aerts, Frank Beurskens, Janine Schuurman, Albert Heck, Kok van Kessel, Suzan Rooijakkers</i>
14.30 – 14.45	21 COMPLEMENT MEDIATED KILLING OF KLEBSIELLA PNEUMONIAE IS AFFECTED BY COLISTIN RESISTANCE MUTATIONS <i>Sjors van der Lans, Axel Janssen, Dennis Doorduijn, Willem van Schaik, Bart Bardoel, Suzan Rooijakkers</i>
14.45 – 15.00	110 FLICK THE SWITCH – SUBCLASS SWITCHING GENERATES A COMPLEMENT-FIXING MONOCLONAL ANTIBODY THAT INHIBITS MALARIA TRANSMISSION <i>Maartje Inklaar, Roos de Jong, Ezra Bekkering, Rianne Stoter, Marga van de Vegte-Bolmer, Geert-Jan van Gemert, Nicholas Proellosch, Matthijs Jore</i>
15.00 – 15.40	HANS MÜLLER EBERHARD PLAQUE, SVAR AWARDS & ECN MEDALS
15.40 – 16.30	Coffee break, Posters, Exhibition, Networking
16.45	Bus departure to Lucerne from vonRoll campus
19.00 – 22.00	Boarding for the Conference Dinner on the lake of Lucerne, Pier 6
22.00 – 24.00	Bus transfer from Lake Lucerne to Bern

MONDAY, AUGUST 29, 2022 – EMCHD MEETING

07.30 – 08.00	Coffee & croissants
08.00 – 09.00	SCIENTIFIC SESSION VII: NEUROLOGICAL & NON-INFECTIOUS DISEASES
	Chairs: Diana Pauly, Jörg Köhl
08.00 – 08.15	5 COMPLEMENT RECEPTOR 1 IS EXPRESSED ON BRAIN CELLS AND IMPACTS ROLES OF MICROGLIAL RELEVANT TO ALZHEIMER'S DISEASE <i>Nikoleta Daskoulidou, Bethany Shaw, Megan Torvell, Sarah Carpanini, Paul Morgan</i>
08.15 – 08.30	6 TERMINAL COMPLEMENT PATHWAY ACTIVATION DRIVES SYNAPTIC LOSS IN ALZHEIMER'S DISEASE MODELS <i>Sarah Carpanini, Megan Torvell, Ryan Bevan, Robert Byrne, Nikoleta Daskoulidou, Takashi Saito, Takaomi Saido, Philip Taylor, Timothy Hughes, Wioleta Zelek, Paul Morgan</i>
08.30 – 08.45	100 10 YEARS FOLLOW-UP OF CD59 CONGENITAL DEFICIENCY: NEUROINFLAMMATION, HEMOLYSIS, ECULIZUMAB, RAVULIZUMAB AND POZELIMAB <i>Dror Mevorach, Netanel Karbian, Marian Zeibak, Itamar Altman</i>
08.45 – 09.00	9 MICE WITH HYPER FUNCTIONAL COMPLEMENT DEVELOP AGE-RELATED NON-ALCOHOLIC STEATOHEPATITIS <i>Beth Gibson, Isabel Pappworth, Harriet Denton, Ola Kamala, Fiona Oakley, Alastair Burt, Kevin Marchbank</i>
09.00 – 10.00	SCIENTIFIC SESSION VIII: THROMBOINFLAMMATION
	Chairs: Robert Rieben, Felix Poppelaars
09.00 – 09.15	166 INFLAMMATORY STIMULI REVEAL A DIFFERENTIAL GLYCOCALYX RESPONSE BETWEEN VENOUS AND ARTERIAL ENDOTHELIAL CELLS LEADING TO DIFFERENCES IN COMPLEMENT DEPOSITION <i>Anastasia Milusev, Michelle Staudenmann, Alain Despont, Jianfang Ren, Robert Rieben, Nicoletta Sorvillo</i>
09.15 – 09.30	165 ACTIVATION OF THE LECTIN PATHWAY OF COMPLEMENT SYSTEM AFTER ISCHEMIC STROKE IN A HUMANIZED MOUSE MODEL EXPRESSING HUMAN MANNOSE-BINDING LECTIN <i>Stefano Fumagalli, Domenico Mercurio, Alessia Valente, Serena Seminara, Gizem Erol, Gregory Stahl, Maria-Grazia De Simoni, Gianluigi Forloni, Luana Fioriti, Franca Orsini</i>
09.30 – 09.45	2 AIR EMBOLI TRIGGER A COMPLEMENT C3-DEPENDENT THROMBOINFLAMMATION IN HUMAN WHOLE BLOOD AND PIGS <i>Benjamin Stage Storm, Judith Ludviksen, Dorte Christiansen, Hilde Fure, Pettersen Kristin, Anne Landsem, Bent Aksel Nielsen, Knut Dybwik, Corinna Lau, John Lambris, Tonje Braaten, Nielsen Erik Waage, Tom Eirik Mollnes</i>

09.45 – 10.00	78 MODULATION OF THE COMPLEMENT TERMINAL PATHWAY AMELIORATES PERITONEAL INJURIES IN A RAT PERITONEAL DIALYSIS MODEL <i>Masashi Mizuno, Naoki Kamegai, Hangsoo Kim, Paul Morgan, Yasuhiro Suzuki, Sosuke Fukui, Hiroshi Kojima, Wioleta Zelek</i>
10.00 – 10.30	Coffee Break, Posters and Exhibition
10.30 – 12.00	SCIENTIFIC SESSION IX: RENAL DISEASES Chairs: Kevin Marchbank, Elena Goicoechea de Jorge
10.30 – 10.45	121 PROPERDIN DEFICIENCY IS PROTECTIVE IN THE C3 GOF MOUSE MODEL OF AHUS <i>Ola Kamala, Kate Smith-Jackson, Harriet Denton, Tom Cox, Isabel Pappworth, David Kavanagh, Kevin Marchbank</i>
10.45 – 11.00	97 FUNCTIONAL CHARACTERIZATION OF AHUS-ASSOCIATED GENETIC VARIANTS IN THE SERINE PROTEASE DOMAIN OF FACTOR B SUGGESTS A NOVEL MECHANISM TO ENHANCE COMPLEMENT ACTIVATION <i>Héctor Martín Merinero, Yuzhou Zhang, Emilia Arjona Bolaños, Renee Goodfellow, Gonzalo Ligero, Elena Gomez Rubio, Sonsoles Martín Santamaría, Richard Smith, Santiago Rodríguez de Córdoba</i>
11.00 – 11.15	74 HUMAN COMPLEMENT C3 GAIN-OF-FUNCTION VARIANT IS RESISTANT TO COFACTOR ACTIVITY LEADING TO EXCESSIVE COMPLEMENT ACTIVATION AND RENAL DISEASE <i>Xiaobo Wu, Zheng Hu, Bryn Webb, Dusan Bogunovic, Bruce Gelb, Dennis Hourcade, John Atkinson</i>
11.15 – 11.30	64 C7 BUT NOT C5AR IS ESSENTIAL TO THE DEVELOPMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME IN THE C3 GAIN-OF-FUNCTION MODEL <i>Kate Smith-Jackson, Patrick Walsh, Ola Kamala, Charlotte Cox, Isabel Pappworth, David Kavanagh, Kevin Marchbank</i>
11.30 – 11.45	115 COPY NUMBER AND SEQUENCE VARIATIONS IN THE FHR1 GENE INFLUENCE COMPLEMENT REGULATION AND COOPERATION WITH COMPLEMENT REGULATORS <i>Luce Perie, Selina Stippa, Andrea Hartmann, Michael Mihlan, Thorsten Wiech, Peter Zipfel</i>
11.45 – 12.00	178 DETECTION OF RENAL C3D DEPOSITION AS A MARKER OF DISEASE ACTIVITY IN LUPUS NEPHRITIS <i>Felix Poppelaars, Brandon Renner, Jennifer Laskowski, Andrew Feemster, Liudmila Kulik, Michael Holers, Joshua Thurman</i>
12.00 – 12.15	Short Break

12.15 – 13.00	CURRENT TOPICS II - FUTURE OF COMPLEMENT ON THERAPEUTICS <i>Speaker: Daniel Ricklin</i> <i>Moderator: Richard Harrison</i>
13.00 – 13.10	ECN GENERAL ASSEMBLY
13.10 – 13.30	Introduction of the next meetings – ICS President, Congress chairpersons of 29 th ICW in 2023 19 th EMCHD in 2024
13.30 – 14.00	TRAVEL AWARDS, POSTER PRESENTATION PRIZES <i>Moderator: Robert Rieben & Reinhard Würzner</i>
14.00	CLOSING CEREMONY– FAREWELL – END OF EMCHD 2022
14.15 – 15.00	Lunch (Lunch bag)
14.30 – 15.55	ECN Board Meeting Meeting room B005, Fab8
14.30 – 15.55	Offered by the CORVOS Program Lecture: “How to make a poster” – Auditorium 001, Fab6 <i>Kali Tal, University of Bern</i>

POSTER EXPO
POSTERS

1	Burt Richards Robert Anstadt, Chris Pappas, Jin Liu, Tana Corsetti, Moussa Zouache, Greg Hageman	QUANTITATIVE TRAIT LOCI INFLUENCING COMPLEMENT FACTOR H-RELATED PROTEIN 4A CONCENTRATION ARE NOT INDEPENDENTLY ASSOCIATED WITH CHROMOSOME 1-DIRECTED AGE-RELATED MACULAR DEGENERATION RISK OR PROTECTION
3	Todor Tschongov Swagata Konwar, Benjamin Fode, Sören Boller, Paulina Dabrowska-Schlepp, Jessika Kleindienst, Karsten Häffner	FUNCTIONAL CHARACTERIZATION OF PASYLATED FORMS OF MOSS PRODUCED HUMAN COMPLEMENT FACTOR H IN VITRO
4	Amanda Heiderscheit M Hall, L Vining, E Goicoechea de Jorge, S Rodriguez de Cordoba, Y Zhang, RJH Smith	ELEVATED FACTOR H-RELATED 1 AND FACTOR H-RELATED 5 ASSOCIATE WITH END STATE KIDNEY DISEASE IN C3 GLOMERULOPATHY
7	Mario Alejandro Duque Villegas Kerstin Walter, Christoph Hölscher, Susanne Homolka, Stefan Niemann, Peter Garred	THE IMPACT OF MBL ON THE OUTCOME OF INFECTION WITH REPRESENTATIVE MYCOBACTERIAL STRAINS OF THE MYCOBACTERIUM TUBERCULOSIS COMPLEX
8	Wioleta Zelek Kate Davies, Rosie Fellows, Matthew Siggins, Eleftheria Kodosaki, Kenneth Baillie, Malcolm Semple, Peter Openshaw, Claire Harris, B. Paul Morgan	COMPLEMENT BIOMARKER PROFILES ACROSS THE SPECTRUM OF DISEASE IN COVID-19 REVEAL ALTERNATIVE PATHWAY DYSREGULATION AS AN EARLY PREDICTOR OF OUTCOME AND MARKER OF SEVERE DISEASE
11	Timo Reiß Hannah I Theis, Joel Vega-Rodriguez, Peter Zipfel, Christine Skerka, Gabriele Pradel	THE ROLE OF PLASMINOGEN FOR RED BLOOD CELL INVASION BY PLASMODIUM FALCIPARUM MEROZOITES
12	Verena Harpf Günter Rambach, Nadia Parth, Magdalena Neurautuer, Verena Fleischer, Cornelia Lass-Flörl, Cornelia Speth, Reinhard Würzner	THE ROLE OF THE COMPLEMENT SYSTEM IN A MURINE MODEL OF DISSEMINATED MUCORMYCOSIS
13	Karolina Smolag-Kłosowska Jakub Olszowka, Rebecca Rosberg, Alexander Pietras, Elisabet Marinko, Karin Leandersson, Paul N Barlow, David O'Connell, Myriam Martin, Anna M Blom,	COMPLEMENT FACTOR H PROMOTES SURVIVAL OF REGULATORY T-CELLS VIA INTERACTION WITH THE INDUCIBLE T-CELLS CO-STIMULATOR (ICOS)
14	Felix Müller Timo Reiss, Peter F Zipfel, Christine Skerka, Gabriele Pradel	THE ROLE OF PF92 IN COMPLEMENT EVASION DURING THE INTRAERYTHROCYTIC REPLICATION PHASE OF THE MALARIA PARASITE PLASMODIUM FALCIPARUM
15	Esther de Boer Marit Jalink, Laura Delvasto-Nuñez, Elisabeth M Meulenbroek, Inge Baas, Susanne R Janssen, Edith E. M. van Dijkman, Kyra Gelderman, Diana Wouters, Marije D. Engel, Masja de Haas, Marie José Kersten, Ilse Jongerius, Sacha Zeerleder, Josephine M. I. Vos	PERITRANSFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN-LABEL PHASE 2 TRIAL
17	Pedro Miguel Coelho Medeiros Leon Cyranka, Anne Rosbjerg, Camilla Schjalm, Peter Garred, Reinhard Würzner, Tom Eirik Mollnes	COMBINED INHIBITION OF COMPLEMENT (C3/C5) AND THE TOLL-LIKE RECEPTORS CO-FACTOR CD14 IN INFLAMMATION INDUCED BY CANDIDA SPP

18	Lauren Fergus Monica Hall, Gabriella Pitcher, Nicole Meyer, Angela Nelson, Stephanie Houston, Jason Misurac, Yuzhou Zhang, Richard J. H. Smith, Carla M. Nester	PREDICTING POST-TRANSPLANT DISEASE RECURRENCE IN C3 GLOMERULOPATHY
19	Kyra Gelderman Tjalle Dijkstra, Angela Kamp, Richard Pouw	DILUTIONAL LINEARITY ISSUES IN COMPLEMENT ACTIVATION MARKER ASSAYS
22	Hang Zhong Ayman Khattab, Elena Magrini, Cecilia Garlanda, Seppo Meri	ROLE OF PENTRAXIN 3 AND INTERACTION WITH COMPLEMENT IN IMMUNE DEFENCE AGAINST MALARIA
23	Emre Can Tüysüz Chrysostomi Gialeli, Eleni Mourati, Karolina Smolag, Elinn Johansson, Alexander Pietras, Anna M. Blom	TUMOR SUPPRESSOR ROLE OF CSMD1 IN GLIOMAS
24	Lucie Colineau Marina McKay, Malin Fex, Ben King, Anna Blom	INVESTIGATING THE ROLE OF C3 IN TYPE 2 DIABETES ONSET USING MOUSE MODELS
25	Laura Pérez-Alós Karen Molyneux, Bengt Fellström, Jonathan Barratt, Peter Garred	TREATMENT WITH TRF-BUDESONIDE (NEFECON) MODULATES THE COMPLEMENT SYSTEM IN PATIENTS WITH IGA NEPHROPATHY
26	Michael Holers Kevin D. Deane, Jennifer A. Seifert, Colin Strickland, Elizabeth Bemis, B. Paul Morgan, Myles J. Lewis, Costantino Pitzalis, Larry W. Moreland, Nirmal Banda	REGIONAL AND CELL-SPECIFIC IMBALANCE OF COMPLEMENT GENE EXPRESSION AND PROTEINS IN THE SYNOVIAL BIOPSIES FROM EARLY RHEUMATOID ARTHRITIS PATIENTS
27	Maximilian Götz Mikkel-Ole Skjoedt, Rafael Bayarri Olmos, Cecilie Bo Hansen, Laura Pérez-Alós, Ida Jarhelt Langpapp, Thomas Lars Benfield, Anne Rosbjerg, Peter Garred	LECTIN PATHWAY ENZYME MASP-2 AND DOWNSTREAM COMPLEMENT ACTIVATION IN COVID-19
28	S. Jin Casper Schalkwijk, Simone Eussen, Annemarie Koster, M. Eline Kooi, Martijn Brouwers, Coen Stehouwer, Marleen MJ van Greevenbroek	PLASMA CONCENTRATIONS OF COMPLEMENT C3 PARTLY EXPLAIN THE ASSOCIATIONS OF MEASURES OF ADIPOSITY WITH TYPE 2 DIABETES: THE MAASTRICHT STUDY
30	Per Nilsson Mieke C. Louwe, Annika E. Michelsen, Karolina Skagen, Vigdis Bjerkeli, Pål Aukrust, Per H. Nilsson, Thor Ueland, Tom Eirik Mollnes, Mona Skjelland, Bente E Halvorsen	ALTERNATIVE AND TERMINAL COMPLEMENT PATHWAY ACTIVATION IN PATIENTS WITH CAROTID ATHEROSCLEROSIS
31	Clemens Spitzenberg Anna Gebhard, Christian Griesche, Cornelia Hermann, Kilian Hoecherl, Simon Streif, Diana Pauly, Antje J Baeumner	DEVELOPMENT OF A FUNCTIONAL COMPLEMENT ASSAY BASED ON LIPOSOMES FOR TOTAL COMPLEMENT ACTIVITY DETERMINATION
32	Silke Huber René René Weiss, Viktoria Weber, Reinhard Würzner, Dorothea Orth-Höller	CIRCULATING EXTRACELLULAR VESICLES – A POTENTIAL BIOMARKER FOR VIRAL BUT NOT BACTERIAL SEPSIS?
33	Janti Haj Ahmad Gabriele Köhl, Jörg Köhl, Andreas Klos	GENERATION OF MONOCLONAL ANTIBODIES TARGETING MURINE C5AR2

35	Cornelia Speth Günter Rambach, Julia Faserl, Magdalena Neurauter, Ruben Bellotti, Bernhard Texler, Georg Schäfer, Dietmar Öfner, Reinhard Würzner, Cornelia Lass-Flörl, Manuel Maglione	RELEVANCE OF COMPLEMENT AND MYCOBIOME DYSBIOSIS FOR PROGRESSION OF PANCREATIC CANCER
36	Carla Plüss Christina Lamers, Céline Leiggerner, Stephanie Anita Vogt, Lorella Ciullo, Marco Tschanz, Riccardo Mancuso, Said Rabbani, Daniel Ricklin	INSIGHT INTO THE INTERACTION PROFILES AND FUNCTIONAL MODULATION OF COMPLEMENT-RELATED INTEGRIN RECEPTORS USING AN INTEGRATED SCREENING PLATFORM
37	Aleksandra Blagoejvic Kevin Widmer, Peter Rüthemann, Soo Jung Lee, Said Rabbani, Markus Lill, Daniel Ricklin	DEVELOPMENT AND EVALUATION OF A PARASITE-DERIVED MODULATOR TO ATTENUATE ADVERSE HOST DEFENSE RESPONSES
38	Reinhard Würzner Silke Huber, Marco Grasse, Doris Wilflingseder, Jörg Köhl, Stefan Niemann, Christoph Hölscher, Cecilia Garlanda, Anna Blom, Suzan Rooijakkers, Seppo Meri, Veronique Premeaux, Peter Garred, Tom Eirik Mollnes, Zoltán Prohászka	CORVOS – FACILITATING MORE PHD STUDENT EXCHANGES AND WORKING TOWARDS A EUROPEAN COMPLEMENT PHD
39	Beatrice Fageräng Corinna Lau, Pedro Miguel Coelho Medeiros, Camilla Schjalm, Karin Ekholt McAdam, Per Nilsson, Peter Garred, Tom Eirik Mollnes,	EVALUATION OF A NOVEL CELL DEPLETION MODEL AND THE CHARACTERIZATION OF CYTOKINE RESPONSE BY INDIVIDUAL CELL POPULATIONS IN THE LEPIRUDIN HUMAN WHOLE BLOOD MODEL
40	Michael Storek Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D'Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M. I. Vos, Nancy Wong, Parija Patel, Xiaoyu Jiang, Deepthi Vagge, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome	INHIBITION OF COMPLEMENT C1S BY SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): EFFICACY AND SAFETY RESULTS FROM THE RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 CADENZA STUDY
41	Michael Storek Ilene Weitz, Yasutaka Ueda, Frank Shafer, Jun Su, Meredith Foster, Parija Patel	INFLAMMATION AND FATIGUE IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): ANALYSIS FROM THE PHASE 3 CARDINAL STUDY
42	Rolf Spirig Ian K Campbell, Fabian Käsermann	RECOMBINANT HUMAN IgG1 FC HEXAMER IS A POTENT MODULATOR OF CLASSICAL PATHWAY ACTIVATION
44	Ben King Damien Bierschenk, Nikolina Papac-Milicevic, Ian Bresch, Serena Bettoni, Mateusz Dziedzic, Susanne Eschenburg, Christoph Binder, Anna Blom	C4B-BINDING PROTEIN INHIBITS PARTICULATE- AND CRYSTAL-INDUCED NLRP3 INFLAMMASOME ACTIVATION
46	Mieke van Essen Emma Peereboom, Nicole Schlagwein, Daniëlle van Gijswijk-Janssen, Tessa Nelemans, Jivan Joeloemsingh, Jurriën Prins, Simon Clark, Christoph Schmidt, Leendert Trouw, Cees van Kooten	PRODUCTION OF COMPLEMENT REGULATORS FACTOR H AND FHL-1 AND COMPLEMENT STABILIZER PROPERDIN BY HUMAN MACROPHAGES
47	Samyr Kenno Jörg Köhl, Sina Borus, Katja Bieber	THE C5A/C5AR1 AXIS CONTROLS THE EARLY IGM TO IgG SWITCH OF COLLAGEN TYPE VII AUTOANTIBODIES IN EXPERIMENTAL EPIDERMOLYSIS BULLOSA ACQUISITA

48	April Baral Claire McKinley, Rosie Fellows, Thomas Hallam, Tom Cox, Daniel Payne, Stephen Richards, Alexandra Pike, Richard Kelly, Morag Griffin, Peter Hillmen, Kevin Marchbank, David Kavanagh, Darren Newton, Claire Harris	COMMON VARIANTS IN C3 AND CR1 ENHANCE COMPLEMENT ATTACK ON PNH ERYTHROCYTES AND INCREASE RISK FOR C3-MEDIATED EXTRAVASCULAR HAEMOLYSIS
50	Ishir Bhan Jonathan Barratt, See Cheng Yeo, Anders J. Fernström, Sean Barbour, C. John Sperati, Russell Villanueva, Ming-Ju Wu, Dazhe Wang, Anna Borodovsky, Prajakta Badri, Elena Yureneva, Ishir Bhan, Daniel Cattran	RESULTS FROM THE PHASE 2 STUDY OF CEMDISIRAN IN ADULT PATIENTS WITH IGA NEPHROPATHY
51	Verena Fleischer Walter Conca, Reinhard Würzner	INTERACTION OF A DISTINCT FCA INTERDOMAIN OLIGOPEPTIDE OF CAMEL IGA WITH THE HUMAN COMPLEMENT SYSTEM
52	Michael Reid Lukas Scheibler, Yiei Zhang, Pascal Deschatelets, Lucas Abraham, Cedric Francois, Wendy Chao, Frank Stout	RESULTS FROM A RANDOMIZED STUDY OF APL-9 IN RESPIRATORY FAILURE, INCLUDING MILD-TO-MODERATE ACUTE RESPIRATORY DISTRESS SYNDROME, (ARDS) DUE TO COVID-19
53	Daria Kowalska Alicja Kuźniewska, Yaiza Senent, Beatriz Tavira, Susana Inogés, Ascensión López-Díaz de Cerio, Ruben Pio, Marcin Okrój, José Ramón Yuste	NON-CANONICAL SOURCE OF ELEVATED C5A LEVELS IN CONVALESCENTS FROM SEVERE COVID-19
55	Alicja Kuźniewska Marta Jaskólska, Kamil Myszczynski, Zbigniew Zdrojewski, Marcin Okrój	OFF-LABEL USE OF ECULIZUMAB FOR THE TREATMENT OF PATIENT WITH NEUROLOGICAL SYMPTOMS AND NON-AMD PROGRESSIVE LOSS OF VISION CARRYING PATHOGENIC FH P.H402Y MUTATION
56	Alicja Kuźniewska Marcin Ziętkiewicz, Marta Jaskólska, Daria Kowalska, Kamil Myszczynski, Zbigniew Zdrojewski, Marcin Okrój	RARE GENETIC VARIANTS OF THE COMPLEMENT SYSTEM GENES IDENTIFIED IN PATIENTS WITH FIBROMYALGIA
57	Ekaterina Umnyakova Said Rabbani, Alyssa Colombi, Clément Bechtler, Avneesh Gautam, Christoph Q. Schmidt, John D. Lambris, Daniel Ricklin	MOLECULAR INSIGHT INTO THE TARGET INTERACTION PROFILE OF THE FACTOR H-BINDING PEPTIDE 5C6
58	Frerich Masson Bart Bardoel, Serena Bettoni, Anna Blom, Suzan Rooijakers	EVASION STRATEGIES OF CLINICAL KLEBSIELLA PNEUMONIAE ISOLATES TO PREVENT RECOGNITION AND KILLING BY HUMAN COMPLEMENT SYSTEM
59	Zhi-Ming Ding Zhi-Ming Ding, Yichen Wang, Vladimir Subbotin, Xiaokai Li, Tao Pei, Maria Afrazi, Holly Hamilton, James Hamilton	SILENCING HEPATIC COMPLEMENT C3 BY RNA INTERFERENCE ALLEVIATES THE PROGRESSION OF RENAL HISTOPATHOLOGICAL LESIONS IN A MOUSE MODEL OF NEPHROPATHY
60	Zhibek Zhumadilova Svetlana Kolesnichenko, Lyudmila Akhmaltdinova	THE CLINICAL-LABORATORY FEATURES OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) IN NEWBORNS COVID-19-INFECTED FROM MOTHER: A CASE SERIES
61	Sára Kellnerová Elisa Varrone, Verena Fleischer, Heribert Talasz, Maurizio Brigotti, Marco Grasse, Dorothea Orth-Höller, Reinhard Würzner	ASSESSMENT OF COMPLEMENT REGULATION BY DIFFERENT STRUCTURAL FORMS OF SHIGA TOXIN 2A

62	Julia Egido Simon O. Dekker, Bart W. Bardoel, Suzan H. M. Rooijakkers, Pieter-Jan Haas	HUMAN COMPLEMENT SYSTEM INHIBITS THERAPEUTIC BACTERIOPHAGES TARGETING PSEUDOMONAS AERUGINOSA
63	Mariam Massri Bettina Sarg, Marco Grasse, Erik Toonen, Mara van Rossum, Dorothee Orth-Höller, Reinhard Würzner	STRONG ASSOCIATION BETWEEN COMPLEMENT C7 AND CLUSTERIN REVEALS A POTENTIAL C7-CLUSTERIN COMPLEX IN CIRCULATION
65	Veronika Ehinger Antje Baeumner, Elena Goicoechea de Jorge, Mihály Józsi, Felix Poppelaars, Richard B. Pouw, Mark-Steven Steiner, Erik J.M. Toonen, Diana Pauly	SCIFIMED - SCREENING OF INFLAMMATION TO ENABLE PERSONALIZED MEDICINE
66	Michael Schwenkert Ali Qamar	CROSS-SPECIES PERFORMANCE OF ILITE(R) C5A-SPECIFIC REPORTER CELL LINE AND OTHER FUNCTIONAL AND BIOMARKER ASSAYS
68	Chloe Connelly Beth Gibson, Balaji Mahendran, Samuel Tingle, Madison Cooper, Ruth Owen, Emily Thompson, Colin Wilson, Neil Sheerin, Kevin Marchbank	INDUCING COMPLEMENT ACTIVATION AND ISCHAEMIC INJURY IN A WHOLE BLOOD MODEL OF EX VIVO NORMOTHERMIC PERfusion OF PORCINE KIDNEYS
69	Remy Muts Dani Heesterbeek, Piet Aerts, Carla de Haas, Bart Bardoel, Suzan Rooijakkers	LABELLING BACTERIAL SURFACES WITH ARTIFICIAL ANTIGENS TO UNRAVEL HOW ANTIBODIES AND COMPLEMENT DRIVE BACTERIAL KILLING
71	Chris Culek Richard Smith, Yuzhou Zhang, Carla Nester	THE IMPORTANCE OF THE MG2+ ION FOR NEPHRITIC FACTOR FUNCTION
72	Björn Laffer Inken Hoffmann, Nicole Muschol, Friederike Köhn, Stephan vom Dahl, György Fekete, Árpád Kovács, Gabriela Riemekasten, Malte Lenders, Karin Heidenreich, Eva Brand, Jörg Köhl	FABRY DISEASE PATIENTS EXERT STRONG COMPLEMENT ACTIVATION INDEPENDENT OF ENZYME REPLACEMENT THERAPY
77	Ann Moyer Sandra Peterson, Laura Train, Susan Lagerstedt, Emily Blake, Linnea Baudhuin	COMPLEMENTARY AMPLICON-BASED AND CAPTURE-BASED NGS APPROACHES FOR ACCURATE AND EFFICIENT COMPLEMENT (CFH AND CFHR LOCUS) GENETIC TESTING
79	Erik Toonen Marloes Michels, Wieke de Bruin, Per Nilsson, Ricardo Brandwijk	PITFALLS IN COMPLEMENT ANALYSIS: A SYSTEMATIC LITERATURE REVIEW OF ASSESSING COMPLEMENT ACTIVATION
80	Xilin Chen Yuanyuan Ma, Cynthia Parker, Juan Wang, Fugang Zhu, William Sheridan, Matthew Davidson, Yarlagadda Babu, Carla Nest	BCX9930, AN ORAL POTENT AND SELECTIVE FACTOR D INHIBITOR, SUPPRESSES COMPLEMENT ALTERNATIVE PATHWAY (AP) C3 CONVERTASE ACTIVITY IN VITRO AND IN PATIENTS WITH COMPLEMENT 3 GLOMERULOPATHY (C3G)
81	Vinaya Dulipati Carmen Chen, Eva Krzyzewska-Dudek, Saija Kiljunen, Juha Kotimaa, Seppo Meri	ENVIRONMENTAL STIMULI AND STRAIN-CHARACTERISTICS REGULATE PROTEOLYTIC CLEAVAGE OF COMPLEMENT FACTORS C3B AND C5 BY PSEUDOMONAS AERUGINOSA
83	Lillemor Skattum Kristoffer Zervides, Birgitta Gullstrand, Jannik Helweg-Larsen, Kerstin Westman, Jakob Thaning Bay, Christina Hansson	SELECTIVE ACQUIRED ABSENCE OF C1R IN SERUM
84	Chantal DUMESTRE-PERARD Federica Defendi, Corentin Leroy, Olivier Epaillard, Giovanna Clavarino, Antoine	COMPLEMENT ALTERNATIVE AND MANNOSE-BINDING LECTIN PATHWAY ACTIVATION IS ASSOCIATED WITH COVID-19 MORTALITY

	<i>Vilotitch, Marion Le Marechal, Marie-Chrisitne Jacob, Tatiana Raskovalova, Martine Pernollet, Audrey Le Gouellec, Jean-Luc Bosson, Pascal Poignard, Matthieu Roustit, Nicole Thielens, Jean-Yves Cesbron</i>	
85	<i>Chantal DUMESTRE-PERARD</i> <i>Paul-Benoit Fargier, Noémie Jourde-Chiche, Françoise Sarrot-Reynauld, Giovanna Clavarino, Federica Defendi, Nicole Thielens, Véronique Rossi, Christine Gaboriaud</i>	AUTOANTIBODIES TARGETING C1S IN SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
87	<i>Stef van der Meulen</i> <i>Rory C Monahan, Tom W.J. Huizinga, Gerda M. Steup-Beekman, Leendert A.Trouw</i>	CIRCULATING LEVELS OF ENDOGENOUS COMPLEMENT INHIBITORS CORRELATE INVERSELY WITH COMPLEMENT CONSUMPTION IN SYSTEMIC LUPUS ERYTHEMATOSUS
88	<i>Christian Karsten</i> <i>Caroline Gruner, Simon Thomsen, Nicola Mohr</i>	COMPLEMENT 5A RECEPTOR 2 (C5AR2) EXPRESSION REGULATES NKP46 LEVELS ON NK CELLS AND INFLUENCES FORMATION OF PULMONARY METASTASES
89	<i>Mikel Rezola Artero</i> <i>Ayman Khattab, Seppo Meri</i>	C4BP HIJACKING BY THE PLASMODIUM FALCIPARUM SPOROZOITE STAGE
91	<i>Carmen Chen</i> <i>Vinaya Dulipati, Juha Kotimaa, Eva Krzyzewska-Dudek, Anna Kolsi, Sheetal Patpatia, Henni Tuomala, Saija Kiljunen, Seppo Meri</i>	COMPLEMENTARY EFFECTS OF BACTERIOPHAGES AND COMPLEMENT ON THE KILLING OF ACINETOBACTER BAUMANNII
93	<i>Silvia González Sanz</i> <i>Marta Subías Hidalgo, Lucía Juana López, Marina Alonso Riaño, Paola Bovolenta Nicolau, Santiago Rodríguez de Córdoba</i>	OCULAR PHENOTYPE IN THE C3DEL923_924 C3-GLOMERULOPATHY MOUSE MODEL
94	<i>Peter Kraiczy</i> <i>Julia Ries, Noura Nouri, Marie Heß, Thomas Wichelhaus, Stephan Göttig, Franco Falcone</i>	CIPA OF ACINETOBACTER BAUMANNII TERMINATES COMPLEMENT-MEDIATED KILLING BY THE FORMATION OF A FACTOR I-MEDIATED, QUADRIPARTITE-ORDERED ASSEMBLAGE
95	<i>Michał Magda</i> <i>Serena Bettoni, Maisem Laabei, Derek Fairley, Thomas Russo, Kristian Riesbeck, Anna Blom</i>	EVASION MECHANISMS USED BY ACINETOBACTER spp. TO ESCAPE THE HUMAN COMPLEMENT SYSTEM
96	<i>Zoltán Prohászka</i> <i>György Sinkovits, János Schnur, Lisa Hurler, Petra Kiszel, Zita Z. Prohászka, Pál Sík, Erika Kajdácsi, László Csernák, Veronika Maráczi, Máté Dávid, Borbála Zsigmond, Éva Rimanóczy, Csaba Bereczki, Loek Willems, Erik Toonen</i>	THERAPY MONITORING OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN USING MACROPHAGE- AND COMPLEMENT ACTIVATION MARKERS
98	<i>Myriam Martin</i> <i>Anna Juto, Albin Björk, Iva Gunnarsson, Anna M. Blom</i>	INVOLVEMENT OF CLASSICAL COMPLEMENT PATHWAY ACTIVATION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
99	<i>Amanda Taylor</i> <i>Nicolò'Ghiringhelli Borsa, Melisha Hanna, Diana Kolbe, Yuzhou Zhang, Michael Jones, Carla Nester, Richard JH. Smith</i>	COPY NUMBER VARIATIONS: A MISSING GENETIC DRIVER IN C3G
102	<i>Marie Kleingarn</i> <i>Christian M Karsten</i>	INFLUENCE OF THE C5A/C5AR1 AXIS ON B-1 LYMPHOCYTE TRAFFICKING AND FUNCTION

103	Erika Kajdácsi Zsófia Polai, Lisa Hurler, György Sinkovits, Petra Kiszel, László Cervenak, Marienn Réti, Péter Gál, Dobó, Steven József. de Maat, Coen Maas, Zoltán Prohászka	LEVELS OF PLASMA SERINE PROTEASE/C1-INHIBITOR COMPLEXES IN SARS-COV-2 INFECTION
105	Jovan Schanzenbacher Jörg Köhl, Christian Marcel Karsten	THE INFLUENCE OF C5AR2 SIGNALING FOR B CELL ACTIVATION IN EARLY AUTOIMMUNITY
106	Linnea Andersson Dick J. Sjöström, Huy Quang Quach, Kim Hägerström, Lisa Hurler, Kerstin Sandholm, Erika Kajdácsi, László Cervenak, Zoltán Prohászka, Erik J. M. Toonen, Camilla Mohlin, Tom Eirik Mollnes, Ivar Tjernberg, Per H Nilsson,	STORAGE OF TRANSFUSION PLATELET CONCENTRATES IS ASSOCIATED WITH COMPLEMENT ACTIVATION AND REDUCED ABILITY OF PLATELETS TO RESPOND TO PAR-1 AND TXA2R-ACTIVATION
107	Alexandra Gerogianni Gro Sørensen, Tom. E. Nilsen Hoel, Karin McAdam, Judith A.K. Ludviksen, Camilla Schjalm, Einar Gude, Dick J. Sjöström, Carola E Henriksson, Camilla Mohlin, Andreas Barratt-Due, Arnt E. Fiane, Tom E. Mollnes, Per H. Nilsson	COMPLEMENT ACTIVATION AND THROMBOINFLAMMATION IN PATIENTS SUBJECTED TO LEFT VENTRICULAR ASSIST DEVICE IMPLANTATION
108	Mikhail Berlov Ilia Krnev, Vladislav Pozolotin, Maria Khaydukova, Nikolay Gorbunov, Valeria Kostevich	STUDY OF THE COMPLEMENT-REGULATING AND ANTIMICROBIAL PROPERTIES OF C3F PEPTIDE
113	Olivera Savic Ivana Jaglicic, Sanja Bajcetic	FUNCTIONAL TESTS OF THE COMPLEMENT SYSTEM IN SERUM SAMPLES BEFORE AND AFTER HEMODIALYSIS
114	Lisanne de Vor Kok van Kessel, Seline Zwarthoff, Maartje Ruyken, Carla de Haas, Piet Aerts, Suzan Rooijakers	CLASSICAL PATHWAY COMPLEMENT ACTIVATION HINDERS INTERACTION OF THE IGG FC-TAIL WITH FC-GAMMA RECEPTOR CD32
117	Renee Goodfellow Nicolo Ghiringhelli Borsa, Amanda Taylor, Carla Nester, Yuzhou Zhang, Richard Smith	A NOVEL C3 VARIANT IN A PATIENT WITH C3 GLOMERULOPATHY
118	Petra Kiszel Pál Sík, Erika Kajdácsi, György Sinkovits, László Cervenak, Zoltán Prohászka	ANTI SARS-COV-2 SPIKE AND NUCLEOCAPSID ANTIBODIES MAY MEDIATE COMPLEMENT DRIVEN INFLAMMATION IN SEVERE COVID-19 PATIENTS
120	Juliane Schikora Stella Schayan-Araghi, Aaron Dort, Diana Pauly	THE RPE-SPECIFIC COMPLEMENT SYSTEM CORRELATES WITH EMT DURING DISEASE DEVELOPMENT
122	Alexander Ekström Konstantinos Papadakos, Piotr Slipek, Eleni Skourtis, Steven Reid, Kristian Pietras, Anna Blom	SUSHI DOMAIN-CONTAINING PROTEIN 4 BINDS TO EPIDERMAL GROWTH FACTOR RECEPTOR AND INITIATES AUTOPHAGY
123	Kevin Widmer Jean-Luc Mary, Corinne Stucki, Alfred Einhaus, Robert A. Brodsky, Elod Koertvely	VASTLY DIFFERENT ALTERNATIVE COMPLEMENT PATHWAY ACTIVATION ON SEEMLY HOMOGENEOUS EUKARYOTIC CELL SURFACES
125	Elena Redondo Yuzhou Zhang, Richard Smith	COMPLEMENT FHR2 IN PATIENTS WITH COMPLEMENT-MEDIATED RENAL DISEASES
127	Kevin Budding Inge Van de Walle, Lill Eva Johansen, Kim Dijkxhoorn, Elisabeth de Zeeuw, Lauri Bloemenkamp, Jeroen Bos, Jeanette Leusen, Hans de Haard, Jeroen Pasterkamp, Leonard	ANTI-C2 ANTIBODY ARGX-117 INHIBITS COMPLEMENT IN A DISEASE MODEL FOR MULTIFOCAL MOTOR NEUROPATHY

	<i>van den Berg, Erik Hack, Peter Boross, Ludo van der Pol</i>	
128	Eline de Boer <i>Marina Sokolova, Anne-Lise Strandmoe, Trond Michelsen, Huy Quach, Viktoria Chaban, Espen Nakstad, Geir Andersen, May-Kristin Torp, Kåre-Olav Stensløkken, Tom Eirik Mollnes, Søren Pischke</i>	MITOCHONDRIAL DNA ACTIVATES THE COMPLEMENT SYSTEM IN A DOSE- AND TIME-DEPENDENT MANNER
129	Antonio Faria <i>Mariana Gaya da Costa, Anita Meter, Mohamed Daha, Felix Poppelaars</i>	THE COMPLEMENT SYSTEM IN PERITONEAL DIALYSIS PATIENTS: INDEPENDENT PATHWAY ACTIVATION OCCURRING AT LOCAL AND SYSTEMIC LEVELS
131	Mariana Gaya da Costa <i>Damodara Gullipalli, Takashi Miwa, Sayaka Sato, Madhu Golla, Xihua Zhu, Jianjun Zhang, Dongqiong Fei, Ping Tsui, Fengkui Zhang, Wen-chao Song</i>	CONTRASTING EFFECTS OF THE FACTOR H-RELATED PROTEIN 1 & 3 GENE DELETION ON RENAL ALLOGRAFT REJECTION IN LIVING VERSUS DECEASED-DONOR KIDNEY TRANSPLANT
132	Takashi Miwa <i>Damodara Gullipalli, Sayaka Sato, Madhu Golla, Xihua Zhu, Jianjun Zhang, Dongqiong Fei, Ping Tsui, Fengkui Zhang, Wen-chao Song</i>	DESIGN AND CHARACTERIZATION OF KP104, A BI-FUNCTIONAL ANTI-C5 MAB AND FH1-5 FUSION PROTEIN THAT SYNERGISTICALLY INHIBITS ALTERNATIVE AND TERMINAL PATHWAYS OF COMPLEMENT ACTIVATION
134	Angela Nelson <i>Yuzhou Zhang, Carla Nester, Richard Smith</i>	LOW FH-TO-FD RATIO INCREASES COMPLEMENT ACTIVITY AND EXACERBATES COMPLEMENT-MEDIATED DISEASES
135	Ole-Lars Brekke <i>Joost Grond, Anne Landsem, Dorthe Christiansen, Judith Anita Krey Ludviksen, Corinna Lau, Trent M Woodruff, John D. Lambris, Terje Espevik, Tom Eirik Mollnes</i>	EFFECTS OF COMPLEMENT C3, C5 AND CD14 INHIBITORS ON BACTERIAL SURVIVAL AND THROMBOINFLAMMATION INDUCED BY TWO DIFFERENT LIVE E.COLI-STRAINS IN HUMAN WHOLE BLOOD
136	Anne Landsem <i>Åse Emblem, Corinna Lau, Hilde Fure, Dorte Christiansen, Judith Ludviksen, Kristin Pettersen, Terje Espevik, John D. Lambris, Trent M. Woodruff, Tom Eirik Mollnes, Ole-Lars Brekke</i>	ESCHERICHIA COLI-INDUCED PLATELET ACTIVATION IS NOT REDUCED BY COMPLEMENT INHIBITION
137	Lisa Hurler <i>Erika Kajdácsi, Erik J.M. Toonen, Bregje van Bree, György Sinkovits, László Csernák, Reinhard Würzner, Zoltán Prohászka</i>	FUNCTIONAL VALIDATION AND REFERENCE RANGE DEFINITION OF EARLY COMPLEMENT ACTIVATION MARKERS C1S/C1-INH AND MASP-1/C1-INH COMPLEXES
138	Eija Nissilä <i>Leo Starck, Elias Aho, Pinja Jalkanen, Ilkka Julkunen, Juha Kotimaa, Karita Haapasalo, Seppo Meri</i>	ANTI-VECTOR ANTIBODIES AGAINST CHADOX1 COVID-19 VACCINE ACTIVATE COMPLEMENT AND PROMOTE PHAGOCYTOSIS OF CHADOX1 IN HEALTHY DONORS
140	Lisa Hurler <i>György Sinkovits, János Schnur, Petra Kiszel, Zita Z. Prohászka, Pál Sík, Erika Kajdácsi, László Csernák, Veronika Maráczi, Máté Dávid, Borbála Zsigmond, Éva Rimanóczy, Csaba Bereczki, Loek Willems, Erik J. M. Toonen, Zoltán Prohászka</i>	COMPLEMENT ACTIVATION IN ACUTE MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN
141	Neda Salimi Afjani <i>Nicolella Sorvillo, Hendrik Jan Ankersmit, Robert Rieben</i>	IRRADIATED APOPTOTIC PERIPHERAL BLOOD MONONUCLEAR CELL SECRETOME (APOSEC) ATTENUATES COMPLEMENT ACTIVATION IN AN IN VITRO XENOTRANSPLANTATION MODEL

142	Vivek Anand Manivel Anna Adler, Osama A. Hamad, Oskar Eriksson, Norbert Lubenow, Bo Nilsson, Kristina Nilsson Ekdahl, Karin Fromell	BINDING AND ACTIVATION OF NATIVE C3 ON ACTIVATED PLATELETS WITHOUT PROTEOLYTIC CLEAVAGE SUGGESTING A NEW ACTIVATION MECHANISM
143	Marco Mannes Rebecca Halbgebauer, Lisa Wohlgemuth David Alexander Christian Messerer, Susa Savukoski, Christoph Q Schmidt, Daniel FÜrst, Morten Hillmer, Reiner Siebert, Oskar Eriksson, Bo Nilsson, Kristina N Ekdahl, Markus Huber-Lang	IS THE COMBINED HETEROZYGOUS GENETIC DEFECT IN C2 AND C8B A REASON FOR MULTIFACETED IMMUNE IMBALANCE?
146	Paolo Macor Sara Capolla, Federico Colombo, Luca De Maso, Prisca Mauro, Thilo Kaehne, Michele Dal Bo, Giuseppe Toffoli	ACTIVATION OF THE COMPLEMENT SYSTEM BY POLYMERIC TARGETED AND UNTARGETED NANOPARTICLES: A COMPARATIVE STUDY BETWEEN HUMAN AND MOUSE SERUM
148	Zoltán Attila Nagy Henriett Barta, József Dobó, Péter Gál, Gábor Pál	ECOTIN HOMOLOGS FROM ESKAPE MICROBES ARE POTENT COMPLEMENT INHIBITORS THAT HAVE CHARACTERISTICALLY DIFFERENT SPECIFICITIES
149	Zoltán Attila Nagy Dávid Héja, Dániel Bencze, Bence Kiss, Eszter Boros, Dávid Szakács, Krisztián Fodor, Matthias Wilmanns, Andrea Kocsis, József Dobó, Péter Gál, Veronika Harmat, Gábor Pál	SYNERGY OF PROTEASE BINDING SITES WITHIN THE ECOTIN HOMODIMER IS CRUCIAL FOR INHIBITION OF MASP ENZYMES AND FOR BLOCKING LECTIN PATHWAY ACTIVATION
150	Isabel Arenas Hoyos Stefanie Hirsiger, Valentina Zollet, Junhua Wang, Josip Mikulic, Lena Fuest, Ahmed Fahiem Emara, Bilal Ben Brahim, Daniela Casoni, Luisana Garcia, Kay Nettelbeck, Olgica Beslac, Hansjoerg Jenni, Maks Mihalj, Alain Despont, Yara Banz, Esther Vögelin, Robert Rieben	COMPARISON OF EX VIVO AND IN VIVO MODELS TO ASSESS REPERFUSION INJURY IN AMPUTATED PIG LIMBS AFTER PROLONGED ISCHEMIA
152	Leon Cyranka Peter Garred, Anne Rosbjerg, Mikkel-Ole Skjødt	CHARACTERIZATION OF C5AR1-BLOCKING MONOCLONAL ANTIBODIES
154	Elod Kortvely Jean-Luc Mary, Corinne Stucki	BIOLAYER INTERFEROMETRY PROVIDES A ROBUST METHOD FOR THE FUNCTIONAL CHARACTERIZATION OF ALTERNATIVE PATHWAY C3-CONVERTASE (C3BBB)
155	László Csernánszky Zsuzsanna Németh, Márta L. Debreczeni, Péter Gál, József Dobó	SYNERGISM BETWEEN COMPLEMENT MASP-1 AND OTHER PRO-INFLAMMATORY FACTORS IN THE ACTIVATION OF ENDOTHELIAL CELLS
156	Camilla Schjalm Eline de Boer, Ida Høy Færden, Anne Lise Strandmoe, Olav Magnus Liavåg, Tobias M. Huijink, Bente Jespersen, Tom Eirik Mollnes, Henri G D. Leuvenink, Søren Erik Pischke	COMPLEMENT ACTIVATION IS INCREASED UPON AIR CONTACT IN OPEN- VERSUS CLOSED-CIRCUIT NORMOTHERMIC MACHINE PERfusion.
157	Sheida Ardestanirajimi Kerstin Sandholm, Camilla Mohlin, Kristina Nilsson Ekdahl	A MODEL TO STUDY COMPLEMENT COMPONENTS IN HUMAN ARPE-19 CELLS ALONE OR IN CO-CULTURE WITH PORCINE RETINA
158	Xiaobo Liu Yuanyuan Wang, Alexander Thomas Bauer, Michael Kirschfink, Karsten Häffner, Stefan Schneider, Christian Gorzelanny	BYSTANDER MECHANISM PROMOTED THE FORMATION OF MEMBRANE ATTACK COMPLEXES ON MELANOMA-ASSOCIATED NEUTROPHILS

159	Ida Høy Færden Camilla Schjalm, Olav Magnus Liavåg, Morten Hagness, Tom Eirik Mollnes, Søren Erik Pischke	COMPLEMENT IS ACTIVATED DURING EX VIVO PORCINE LIVER MACHINE PERfusion INDEPENDENT OF EXISTING LIVER INJURY
160	Barbro Persson Kerstin Sandholm, Patrik Nordenfelt, Janne Björkander, Carl-Fredrik Wahlgren, Alberto López-Lera, Margarita López Trascasa, Kristina Nilsson Ekdahl, Bo Nilsson	NEW BIOMARKERS FOR NON-C1INH ASSOCIATED HEREDITARY ANGIOEDEMA
163	Anne Rosbjerg Maximillian Götz, Mikkel-Ole Skjødt, Peter Garred	COMPLEMENT FEEDBACK MECHANISM DETACHES MBL AND C1Q FROM THEIR TARGETS
164	Leo Starck Juha Kotimaa, Sheetal Patpatia, Saima Kiljunen, Seppo Meri	A HIGH-THROUGHPUT SERUM BACTERICIDAL ASSAY IN EVALUATING COMPLEMENT-MEDIATED KILLING OF KEY GRAM-NEGATIVE CLINICAL BACTERIAL ISOLATES
167	Serena Bettoni Mateusz Dziedzic, Damiën Bierschenk, Ben C. King, Kristian Riesbeck, Anna M Blom	C4B BINDING PROTEIN PROTECTS GROUP A STREPTOCOCCI FROM PHAGOCYTIC KILLING THROUGH INTERNALIZATION IN HUMAN MACROPHAGES AND INHIBITION OF INFLAMMASOME
168	Irene Gómez Delgado Fernando Corvillo, Laura González Sánchez, Antonio Bouthelier, Marta Melgosa, Teresa Olea, Pilar Sánchez-Corral	FACTOR H AND FACTOR H-RELATED PROTEINS SHOW DIFFERENT EXPRESSION PROFILES IN HEALTHY CONTROLS AND IGA NEPHROPATHY PATIENTS
170	Jessica Susann Kleer Lillemor Skattum, Min Jeong Kim, Marten Trendelenburg	COMPLEMENT C1S DEFICIENCY IN A MALE CAUCASIAN PATIENT WITH SYSTEMIC LUPUS ERYTHEMATOSUS
171	Rachel Hevey Said Rabbani, Deborah Berta, Daba-Rokhya Diaye, Niklas Winter, Maria Ruggli, Tobias Wicher, Tobias Brunner, Mergim Maraj Martinez, Edvin Puric, Gisèle Truong, Martin Smieško, Daniel Ricklin	THE DEVELOPMENT OF GLYCOMIMETIC COLLECTIN-11 ANTAGONISTS IN EFFORTS TO LIMIT ISCHEMIA-REPERFUSION INJURY
172	Daba-Rokhya NDiaye Said Rabbani, Tobias Wicher, Rachel Hevey, Daniel Ricklin	DEVELOPMENT OF BIOASSAYS TO EVALUATE THE INTERACTION PROFILES OF CARBOHYDRATE-BASED LIGANDS AND MODULATORS OF LECTIN TARGETS WITHIN THE COMPLEMENT SYSTEM
174	Sayaka Sato Takashi Miwa, Damodar Gullipalli, Lin Zhou, Jianjun Zhang, Xiaoxia Hu, Bingbing Jiang, Ping Tsui, Wen-Chao Song	THERAPEUTIC EFFICACY OF A BI-FUNCTIONAL ANTI-C5 MAB/FH1-5 FUSION PROTEIN IN A MOUSE MODEL OF RAPIDLY PROGRESSING LETHAL C3 GLOMERULOPATHY
175	Leonardo Cecotto Saber Amin Yavari, Charles Vogely, Bart van der Wal, Harrie Weinans, Kok van Kessel, Jos van Strijp	COMPLEMENT- AND ANTIBODY-MEDIATED PHAGOCYTOSIS OF STAPHYLOCOCCUS AUREUS: MACROPHAGES AND NEUTROPHILS IN COMPARISON
176	Jutta Schroeder-Braunstein Thomas Giese, Leonie Schumacher, Renate Rutz, Daniel Fischer, Stefanie Klevenz, Sabine Wentrup, Sylvia Parthe, Guido Wabnitz, Michael Kirschfink, Uta Merle	PERSISTENT COMPLEMENT ACTIVATION FOLLOWING SARS-COV-2 INFECTION
177	Alexandra Tünde Matola Eszter Szarka, György Nagy, Bernadette Rojkovich, Gabriella Sármay, Mihály Józsi, Barbara Uzonyi	AUTOANTIBODIES TO COMPLEMENT COMPONENTS IN RHEUMATOID ARTHRITIS

179	Gizem Erol Patricia Perez Schmidt, Alessia Pancaro, Javier M. Melo Diaz, Africa G. Barrientos, John Porter, Laura Polito, Michal Szymonik, Inge Nelissen, Daniel I.R. Spencer, Arianna Piotti, Marten Beeg, Maria-Grazia De Simoni, Stefano Fumagalli, Marco Gobbi	MANNOSE BINDING LECTIN SPECIFIC NANO-INHIBITORS AND THEIR POTENTIAL USE AS NEUROPROTECTIVE AGENTS
180	Nicole Schäfer Magdalena Zborilova, Markus Böhm, Brian Johnstone, Susanne Grässel	A-MSH MODULATES COMPLEMENT ACTIVATION AND INFLAMMATORY STATE OF SENESCENT HUMAN OSTEOARTHRITIC CHONDROCYTES
182	Anas Abu-Humaidan Fatima M. Ahmad, Dima Awajan, Raba'a F. Jarrar, Nader Alaridah	ANTI-SARS-COV-2 S-RBD IGG FORMED AFTER BNT162B2 VACCINATION CAN BIND C1Q AND ACTIVATE COMPLEMENT
184	Rabia Ülkü KORKMAZ Peter Konig, Joerg Koehl, Ian Lewkowich, Yves Laumonnier	C5A SIGNALLING IN MYELOID CELLS REGULATES ILC2 DEVELOPMENT THROUGH UNIQUE, CELL-DEPENDENT MECHANISMS
185	Cox Daan Larisa Chernyaeva, Satoshi Fudo, Shahar Syed1, Katarzyna Leskinen, Päivi Saavalainen, Tarja Myntti, Minna Tikkanen, Eija Nissilä, Karita Haapasalo	GROUP B STREPTOCOCCUS VIRULENCE FACTORS AND THEIR INTERACTIONS WITH THE COMPLEMENT SYSTEM
186	Junhua Wang Stefanie Hirsgier, Christine Lee, Lena Fuest, Bilal Ben Brahim, Valentina Zollet, Isabel Arenas Hoyos, Daniela Casoni, Hansjoerg Jenni, Alain Despont, Kay Nettelbeck, Luisana García, Yara Banz, Kirsten Irmler, Carole Gygax, Jane Shaw-Boden, Nicoletta Sorvillo, Esther Vögelin, Robert Rieben	C1-INHIBITOR IS PROTECTIVE AGAINST LOCAL AND REMOTE REPERFUSION INJURY OF AMPUTATED PIG LIMBS AFTER PROLONGED ISCHEMIA
187	Nathaniel Parsons Balasubramaniam Annamalai, Bärbel Rohrer	REGULATABLE COMPLEMENT INHIBITION OF THE ALTERNATIVE PATHWAY MITIGATES AGE-RELATED MACULAR DEGENERATION PATHOLOGY
188	Neda Salimi Afjani Nicolai Bovin, Olga Zubkova, Robert Rieben	THE SULPHATED GLYCOLIPID SU7MALT-SP6-C2HN3-CMG2-AD-DE ATTENUATES COMPLEMENT ACTIVATION IN AN IN VITRO XENOTRANSPLANTATION MODEL
190	Tiphaine Ruggeri Yasmin De Wit, Noëlia Schärz, Anne Angelillo-Scherrer, Justine Brodard, Anja ten Brinke, Cédri Hirzel, Ilse Jongerius, Sacha Zeerleder	DEVILS DANCE: COMPLEMENT, NETS IN IMMUNO-THROMBOSIS OF COVID-19
191	Johanna Oechtering Kerstin Stein, Sabine Schädelin, Marguerite Limberg, Annette Orleth, Aleksandra Maceski, Stephanie Meier, Eline Willems, Ferhan Qureshi, Fatima Rubio Da Costa, Wayne Hu, Ingmar Heijnen, Axel Regeniter, Tobias Derfuss, Pascal Benkert, Heinz Wiendl, Cristina Granziera, Ludwig Kappos, Marten Trendelenburg, David Leppert, Jan Luenemann, Jens Kuhle	COMPARTMENTALIZED EARLY CASCADE COMPLEMENT ACTIVATION PREDICTS DISEASE SEVERITY IN MULTIPLE SCLEROSIS

POSTER AUTHORS INDEX

Abu-Humaidan,	A.	182	Heiderscheit,	A.	4
Andersson,	L.	106	Hevey,	R.	171
Ardeshirilajimi,	S.	157	Holers,	M.	26
Arenas Hoyos,	I.	150	Huber,	S.	32
Attila Nagy,	Z.	148	Hurler,	L.	137
Attila Nagy,	Z.	149	Hurler,	L.	140
Baral,	A.	48	Høy Færden,	I.	159
Berlov,	M.	108	Jin,	S.	28
Bettoni,	S.	167	Kajdácsi,	E.	103
Bhan,	I.	50	Karsten,	C.	88
Brekke,	O-L.	135	Kellnerová,	S.	61
Budding,	K.	127	Kenno,	S.	47
Can Tüysüz,	E.	23	King,	B.	44
Cecotto,	L.	175	Kiszel,	P.	118
Cervenak,	L.	155	Kleer,	J.	170
Chen,	C.	91	Kleingarn,	M.	102
Chen,	X.	80	Kortvely,	E.	154
Coelho Medeiros,	P.	17	Kowalska,	D.	53
Colineau,	L.	24	Kraiczy,	P.	94
Connelly,	C.	68	Kuźniewska,	A.	55
Cox,	D.	185	Kuźniewska,	A.	56
Culek,	C.	71	Laffer,	B.	72
Cyranka,	L.	152	Landsem,	A.	136
de Boer,	E.	128	Liu,	X.	158
de Boer,	E.	15	Macor,	P.	146
de Vor,	L.	114	Magda,	M.	95
Ding,	Z.	59	Manivel,	V.	142
Dulipati,	V.	81	Mannes,	M.	143
Dumestre-Perard,	C.	84	Martin,	M.	98
Dumestre-Perard,	C.	85	Masson,	F.	58
Duque Villegas,	M.	7	Massri,	M.	63
Egido,	J.	62	Miwa,	T.	132
Ehinger,	V.	65	Moyer,	A.	77
Ekstrom,	A.	122	Muts,	R.	69
Erol,	G.	179	Müller,	F.	14
Fageräng,	B.	39	Ndiaye,	D-R.	172
Faria,	A.	129	Nelson,	A.	134
Fergus,	L.	18	Nilsson,	P.	30
Fleischer,	V.	51	Nissilä,	E.	138
Gaya da Costa,	M.	131	Oechtering,	J.	191
Gelderman,	K.	19	Parsons,	N.	187
Gómez Delgado,	I.	168	Pérez-Alós,	L.	25
González Sanz,	S.	93	Persson,	B.	160
Goodfellow,	R.	117	Plüss,	C.	36
Götz,	M.	27	Prohászka,	Z.	96
Haj Ahmad,	J.	33	Redondo,	E.	125
Harpf,	V.	12	Reid,	M.	52

Reiß,	T.	11	Toonen,	E.	79
Rezola Artero,	M.	89	Tschongov,	T.	3
Richards,	B.	1	Tünde Matola,	A.	177
Rosbjerg,	A.	163	Umnyakova,	E.	57
Ruggeri,	T.	190	van der Meulen,	S.	87
Salimi Afjani,	N.	141	van Essen,	M.	46
Salimi Afjani,	N.	188	Wang,	J.	186
Sato,	S.	174	Widmer,	K.	123
Savic,	O.	113	Würzner,	R.	38
Schanzenbacher,	J.	105	Ülkü Korkmaz,	R.	184
Schikora,	J.	120	Zelek,	W.	8
Schjalm,	C.	156	Zhong,	H.	22
Schroeder-Braunstein,	J.	176	Zhumadilova,	Z.	60
Schwenkert,	A.	66			
Schäfer,	N.	180			
Skattum,	L.	83			
Smolag-Kłosowska,	K.	13			
Speth,	D.	35			
Spirig,	R.	42			
Spitzenberg,	C.	31			
Starck,	L.	164			
Storek,	M.	40			
Storek,	M.	41			
Taylor,	A.	99			

**LATE BREAKING
POSTERS**

LBP-3	Flóra Demeter	THE DETRIMENTAL SYNERGISTIC EFFECT OF HYPOXIA AND COMPLEMENT MASP-1 IN THE ATHEROSCLEROSIS-RELATED DISEASES, ON ENDOTHELIAL CELL MODEL
LBP-5	Eun-Ae Yang <i>Ha Eun Jeon, Eun-Ae Yang, Jung Woo Rhim</i>	EFFECTIVENSS OF MONTELUKAST IN OVALBUMIN-INDUCED FOOD ALLERGY MOUSE MODEL
LBP-6	Sandra Wyman <i>Marcel Mischnik, David Leong, Subhajit Ghosh, Xiahui Tan, Helen Cao, Benjamin Kuehnemuth, Glenn A. Powers, Partho Halder, Mitchell De Souza, Hannah S. James, Vesna Tomasetig, Holger Lind, Paolo Rossato, Catherine M. Owczarek, Saw Yen Ow, Steven K. Dower, Adriana Baz Morelli, Tony Rowe, Matthew P. Hardy</i>	PHARMACOKINETIC AND PHARMACODYNAMIC CHARACTERIZATION OF CSL040
LBP-7	Michael Storek <i>Vaishnavi Rajagopal, Nina Leksa, Ronald Gorham, Siddharth Jindal, Kevin Knockenhauer, Tony Byu, Joanne Chan, Courtney Mercadante, Stephen Moore, Sandip Panicker, Graham Parry</i>	SAR443809: A POTENT AND SELECTIVE INHIBITOR OF THE ALTERNATIVE PATHWAY OF COMPLEMENT, TARGETING COMPLEMENT FACTOR BB
LBP-8	Michael Storek <i>Ken Simmons, Joanne Chan, Sami Hussain, Eileen L Rose, Kate Markham, Tony S Byun, Sandip Panicker, Graham C Parry</i>	SAR445088, A MONOCLONAL ANTIBODY SPECIFIC FOR THE ACTIVE FORM OF C1S IS A POTENT INHIBITOR OF THE CLASSICAL PATHWAY OF COMPLEMENT
LBP-9	Michael Osthoff <i>Pascal Urwyler, Marina Leimbacher, Panteleimon Charitos, Stephan Moser, Ingmar Heijnen, Marten Trendelenburg, Reto Thoma, Adrián Camacho-Ortiz, Marcelo Bacci, Lars Huber, Melina Stüssi-Helbling, Werner Albrich, Parham Sendi</i>	RECOMBINANT HUMAN C1 ESTERASE INHIBITOR (CONESTAT ALFA) IN THE PREVENTION OF SEVERE SARS-COV-2 INFECTION IN HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, OPEN-LABEL, MULTI-CENTER TRIAL.
LBP-10	Henry Chen <i>An Pham, Naomi Patel, Yuqing Zhang, David Jayne, Peter Merkel, Huibin Yue, Pirow Bekker, John Stone</i>	DIFFERENCES BETWEEN AVACOPAN AND PREDNISONE FOR THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS AT DIFFERENT THRESHOLDS OF GLUCOCORTICOID TOXICITY
LBP-11	An Pham <i>Ulrich Specks, Peter Merkel, David Jayne</i>	INSIGHTS FROM THE ADVOCATE STUDY: RESPIRATORY TRACT INVOLVEMENT IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF AVACOPAN
LBP-12	Rohini Manickam <i>Jeremy Rotty</i>	ROLES OF CYTOSKELETON PROTEINS ARP2/3 AND PHACTR4 IN COMPLEMENT MEDIATED PHAGOCYTOSIS

LBP-13	Pratiti Banerjee Aaron Dort, Diana Pauly	A VERY LITTLE KEY TO A VERY HEAVY DOOR: PHAGE DISPLAY DERIVED NOVEL PEPTIDE BINDERS SHOW SIGNIFICANT BINDING AFFINITY TO FACTOR-H RELATED PROTEIN-3 (FHR-3)
LBP-14	Dick Sjöström Alexandra Gerogianni, Melissa Bal, Camilla Mohlin, Tom Eirik Mollnes, Per H. Nilsson	IRON OXIDE NANOPARTICLE-INDUCED ENDOTHELIAL CELL ACTIVATION IS COUNTERACTED BY TARGETING COMPLEMENT C3 AND C5 IN A HUMAN WHOLE BLOOD AND ENDOTHELIAL CELL MODEL
LBP-15	Toshihiro Sawai	ACH50 TEST CAN HELP DETERMINE TREATMENT STRATEGY FOR DRUG-INDUCED TMA
LBP-16	Bert Veuskens Mieke C. Brouwer, Mark Hoogenboezem, Ilse Jongerius, Richard B. Pouw	NEW ANTIBODIES TO MEASURE DIMERIZATION OF FACTOR H-RELATED PROTEIN 2
LBP-17	An Pham Vibeke Strand, Pirow Bekker, Huibin Yue, David R.W. Jayne, Peter Merkel	EFFECT OF THE C5A RECEPTOR INHIBITOR AVACOPAN ON HEALTH-RELATED QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS
LBP-18	Henry Chen Peter Merkel, Huibin Yue, Emil DeGoma, Pirow Bekker, David Jayne	EFFECT OF AVACOPAN ON RELAPSE RATES AND RELAPSE-FREE TIME IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS, RESULTS OF THE PHASE 3 ADVOCATE STUDY
LBP-19	Kathleen Sullivan Chris Li, Carolyn Dunlap, Niky Zhao, Linda Ertl, Zhenhua Miao, Israel Charo, Thomas Schall	C5A AND C5AR ARE PROMINENTLY ASSOCIATED WITH TUNNELS IN SEVERE HIDRADENITIS SUPPURATIVA
LBP-20	Kathleen Sullivan Chris Li, Carolyn Dunlap, Niky Zhao, James Kilgour, Aatman Shah, Karen Ebsworth, Israel Charo, Kavita Sarin, Thomas Schall	COMPLEMENT C5A RECEPTOR IN MACROPHAGE-MEDIATED RENAL INFLAMMATION AND FIBROSIS IN LUPUS NEPHRITIS
LBP-21	Henry Chen David R.W. Jayne, Peter Merkel, Pirow Bekker, Annette Bruchfeld, Duvuru Geetha, Alexandre Karras, John Niles	EFFECT OF AVACOPAN, A C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS
LBP-22	Hannah Wolf Larissa Gümpelein, Joachim Havla, Diana Pauly	C3A-MEDIATED ENDOTHELIAL BARRIER DISRUPTION IS ATTENUATED BY C5A IN NEUROMYELITIS OPTICA
LBP-23	Adrian Sutta Nelia Nina Leemans, Anne Rosbjerg, Christian del Agua Villa, Adam S. Vincek, Tomás de Garay, Laura Pérez-Alós, Keith Rivera, Rafael Bayarri-Olmos	COLEC11 SPLICE VARIANTS FOUND IN THE CIRCULATION ARE FUNCTIONALLY DISTINCT IN THEIR INTERACTION WITH CL-10 AND THE MASP-2
LBP-24	Sigridur Sunna Aradottir Ann-Charlotte Kristoffersson, Brynjar Jensson, Patrick Sulem, Henning Gong, Runolfur Palsson, Diana Karpman	MONOZYGOTIC TWINS WITH A FACTOR B MUTATION AND DISCORDANT PRESENTATION OF ATYPICAL HEMOLYTIC UREMIC SYNDROME

LBP-26	Cecilie Bo Hansen Håkon Sandholdt, Maria Elizabeth Engel Møller, Laura Pérez-Alós, Lise Pedersen, Simone Bastrup Israelsen, Peter Garred, Thomas Benfield	PREDICTION OF RESPIRATORY FAILURE AND MORTALITY IN COVID-19 PATIENTS USING LONG PENTRAXIN PTX3
LBP-27	Bruce Burnett Pieter van Paassen	DOUBLE-BLIND, PLACEBO-CONTROLLED RANDOMIZED PHASE 3 STUDY IN CRITICALLY ILL MECHANICALLY VENTILATED COVID-19 PATIENTS INVESTIGATING VILOBELIMAB'S EFFECT, AN ANTI-C5A MAB, ON 28-DAY ALL-CAUSE MORTALITY
LBP-29	Gabriella Guzzo Salima Sadallah, Isabelle Bassi, Giuseppe Pantaleo, Manuel Pascual, Daniel Teta	SC5B-9 AND BB FACTOR LEVELS AS POTENTIAL NOVEL BIOMARKERS IN CRESCENTIC IGA NEPHROPATHY
LBP-30	Peter Rüthemann Aleksandra Blagojevic, Markus Lill, Daniel Ricklin	EXPLORING THE TARGET SELECTIVITY OF A LEECH-DERIVED SMALL PROTEIN TOWARDS COMPLEMENT SERINE PROTEASES USING COMPUTATIONAL METHODS
LBP-31	David Eikrem Karin Fromell, Kristina Nilsson Ekdahl, Bo Nilsson, Vivek anand Manivel	A METHODICAL INVESTIGATION OF THE CROSSTALK BETWEEN THE LECTIN PATHWAY AND THE CONTACT/KALLIKREIN SYSTEM
LBP-32	Laura Lucientes Continente Marina Alonso Riaño, Lucia Juana Lopez, Santiago Rodriguez de Córdoba, Elena Goicoechea de Jorge, Bárbara Márquez Tirado	DYSREGULATION OF THE COMPLEMENT ALTERNATIVE PATHWAY EXACERBATES RENAL DAMAGE IN AN EXPERIMENTAL MODEL OF MPO-ASSOCIATED VASCULITIS.
LBP-33	Bárbara Márquez Tirado Héctor Martín Merinero, Eva Calviño Vanegas, Laura Lucientes Continente, Francisco Javier Cañadas Vicinay, Santiago Rodríguez de Córdoba, Elena Goicoechea de Jorge	THE C-TERMINUS OF FHR-5 INTERACTS WITH C3B AND 2,3'- SIALIC ACID SUGGESTING ITS POTENTIAL TO DE-REGULATE FH ON HOST CELL SURFACES

LATE BREAKING POSTER AUTHORS INDEX

Aradottir,	S.	LBP-24	Pham,	A.	LBP-11
Banerjee,	P.	LBP-13	Pham,	A.	LBP-17
Bo Hansen,	C.	LBP-26	Rüthemann,	P.	LBP-30
Burnett,	B	LBP-27	Sjöström,	D.	LBP-14
Chen,	H.	LBP-10	Storek,	M.	LBP-8
Chen,	H.	LBP-21	Storek,	M.	LBP-7
Chen,	H.	LBP-18	Sullivan,	K.	LBP-19
Demeter,	F.	LBP-3	Sullivan,	K.	LBP-20
Eikrem,	D.	LBP-31	Sutta,	A.	LBP-23
Guzzo,	G.	LBP-29	Veuskens,	B.	LBP-16
Lucienete	L.	LBP-32	Wolf,	H.	LBP-22
Continete,			Wymann,	S.	LBP-6
Manickam,	R.	LBP-12	Yang,	E.	LBP-5
Márquez Tirado,	B.	LBP-33			
Osthoff,	M.	LBP-9			

SPONSORS

This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.

EMCHD 2022 Organizing Committee wishes to express its gratitude to all sponsors and exhibitors.

Platinum Sponsor



Silver Sponsor

Exhibitors



Remote sponsors



Supporter

